Please sign in to follow a disease.
Head and neck neoplasm
MONDO:0005586A benign or malignant neoplasm that affects the anatomic structures of the head and neck region. Representative examples of benign neoplasms include salivary gland pleomorphic adenoma and nasal cavity papilloma. Representative examples of malignant neoplasms include oral cavity squamous cell carcinoma, laryngeal squamous cell carcinoma, and salivary gland carcinoma.
Also known as: craniocervical region neoplasm, craniocervical region neoplasm (disease), craniocervical region tumor, craniocervical region tumour, head and neck neoplasm, head and neck neoplasm (excluding central nervous system), head and neck tumor, head and neck tumour
3518 clinical trials for this condition and its sub-types, 79 tagged with Head and neck neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Head and neck neoplasm
-
Head and neck cancer 638 trials · 2,010 incl. sub-types
16 sub-types
- Head and neck carcinoma 74 trials · 1,420 incl. sub-types Sub-types →
- Malignant tumor of neck 14 trials · 507 incl. sub-types Sub-types →
- Ocular cancer 10 trials · 168 incl. sub-types Sub-types →
- Salivary gland cancer 62 trials · 81 incl. sub-types Sub-types →
- Skull cancer 0 trials · 38 incl. sub-types Sub-types →
- Tongue cancer 26 trials · 35 incl. sub-types Sub-types →
- Lip cancer 12 trials · 15 incl. sub-types Sub-types →
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Malignant cranial nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Cheek mucosa cancer 1 trial · 2 incl. sub-types Sub-types →
- Gingival cancer 1 trial · 2 incl. sub-types Sub-types →
- Malignant ear neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Malignant tumor of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
- Hard palate cancer 0 trials · 1 incl. sub-types Sub-types →
- Angiosarcoma of the scalp 0 trials
- Malignant carotid body paraganglioma 0 trials
-
Neoplasm of neck 1 trial · 507 incl. sub-types
4 sub-types
- Malignant tumor of neck 14 trials · 507 incl. sub-types Sub-types →
- Benign neoplasm of neck 0 trials
- Cervical dermoid cyst 0 trials
- Cervical neuroblastoma 0 trials
-
Neoplasm of oropharynx 3 trials · 280 incl. sub-types
2 sub-types
- Oropharynx cancer 150 trials · 280 incl. sub-types Sub-types →
- Benign neoplasm of oropharynx 0 trials
-
Nasopharyngeal neoplasm 37 trials · 226 incl. sub-types
3 sub-types
- Malignant tumor of nasopharynx 9 trials · 214 incl. sub-types Sub-types →
- Benign neoplasm of nasopharynx 0 trials
- Nasopharyngeal teratoma 0 trials
-
Eye neoplasm 3 trials · 192 incl. sub-types
13 sub-types
- Ocular cancer 10 trials · 168 incl. sub-types Sub-types →
- Uvea neoplasm 1 trial · 103 incl. sub-types Sub-types →
- Retina neoplasm 2 trials · 36 incl. sub-types Sub-types →
- Conjunctival tumor 1 trial · 23 incl. sub-types Sub-types →
- Benign neoplasm of eye 0 trials · 19 incl. sub-types Sub-types →
- Cornea neoplasm 0 trials · 17 incl. sub-types Sub-types →
- Eyelid neoplasm 3 trials · 7 incl. sub-types Sub-types →
- Intraocular medulloepithelioma 1 trial
- Ocular surface squamous neoplasia 1 trial
- Combined hamartoma of the retina and retinal pigment epithelium 0 trials
- Lacrimal gland neoplasm 0 trials Sub-types →
- Orbital leiomyoma 0 trials
- Ring dermoid of cornea 0 trials
-
Skull neoplasm 0 trials · 161 incl. sub-types
7 sub-types
- Skull base neoplasm 12 trials · 124 incl. sub-types Sub-types →
- Skull cancer 0 trials · 38 incl. sub-types Sub-types →
- Paranasal sinus neoplasm 5 trials · 29 incl. sub-types Sub-types →
- Neoplasm of jaw 1 trial · 9 incl. sub-types Sub-types →
- Orbit neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Jugular foramen meningioma 0 trials
- Schwannoma of jugular foramen 0 trials
-
Neoplasm of hypopharynx 0 trials · 100 incl. sub-types
3 sub-types
- Hypopharynx cancer 50 trials · 100 incl. sub-types Sub-types →
- Benign neoplasm of hypopharynx 0 trials Sub-types →
- Epiglottis neoplasm 0 trials Sub-types →
-
Tumor of salivary gland 9 trials · 85 incl. sub-types
4 sub-types
- Salivary gland cancer 62 trials · 81 incl. sub-types Sub-types →
- Neoplasm of major salivary gland 0 trials · 17 incl. sub-types Sub-types →
- Benign neoplasm of salivary gland 1 trial · 5 incl. sub-types Sub-types →
- Neoplasm of minor salivary gland 0 trials Sub-types →
-
Nasal cavity and paranasal sinus neoplasm 0 trials · 44 incl. sub-types
1 sub-type
- Nasal cavity and paranasal sinus carcinoma 21 trials · 44 incl. sub-types Sub-types →
-
Tongue neoplasm 2 trials · 35 incl. sub-types
2 sub-types
- Tongue cancer 26 trials · 35 incl. sub-types Sub-types →
- Benign neoplasm of tongue 0 trials
-
Lip neoplasm 1 trial · 15 incl. sub-types
2 sub-types
- Lip cancer 12 trials · 15 incl. sub-types Sub-types →
- Benign neoplasm of lip 0 trials
-
Nasal cavity neoplasm 1 trial · 15 incl. sub-types
3 sub-types
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Benign neoplasm of nasal cavity 1 trial Sub-types →
- Nasal cavity inverting papilloma 0 trials
-
Benign epithelial tumor of salivary glands 0 trials · 12 incl. sub-types
1 sub-type
- Pleomorphic adenoma 12 trials
-
Recurrent respiratory papillomatosis 8 trials · 9 incl. sub-types
1 sub-type
- Laryngeal papillomatosis 1 trial
-
Cranial nerve neoplasm 0 trials · 8 incl. sub-types
12 sub-types
- Malignant cranial nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Olfactory nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Optic nerve neoplasm 1 trial · 4 incl. sub-types Sub-types →
- Abducens nerve neoplasm 0 trials
- Facial nerve neoplasm 0 trials
- Glossopharyngeal nerve neoplasm 0 trials Sub-types →
- Hypoglossal nerve neoplasm 0 trials Sub-types →
- Oculomotor nerve neoplasm 0 trials Sub-types →
- Spinal accessory nerve neoplasm 0 trials
- Trigeminal nerve neoplasm 0 trials Sub-types →
- Trochlear nerve neoplasm 0 trials
- Vestibulocochlear nerve neoplasm 0 trials Sub-types →
-
Tonsil neoplasm 0 trials · 8 incl. sub-types
2 sub-types
- Tonsil cancer 5 trials · 8 incl. sub-types Sub-types →
- Benign neoplasm of tonsil 0 trials Sub-types →
-
Odontogenic neoplasm 0 trials · 5 incl. sub-types
4 sub-types
- Keratocystic odontogenic tumor 3 trials
- Ameloblastoma 2 trials Sub-types →
- Ameloblastic carcinoma 0 trials
- Calcifying epithelial odontogenic tumor 0 trials
-
Ocular adnexal lymphoma 4 trials
-
Malignant epithelial tumor of salivary glands 0 trials · 4 incl. sub-types
1 sub-type
-
Ear neoplasm 0 trials · 3 incl. sub-types
5 sub-types
- Malignant ear neoplasm 0 trials · 2 incl. sub-types Sub-types →
- External ear neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Inner ear neoplasm 0 trials · 1 incl. sub-types Sub-types →
- Neoplasm of middle ear 0 trials · 1 incl. sub-types Sub-types →
- Benign neoplasm of ear 0 trials Sub-types →
-
Familial thyroglossal duct cyst 2 trials
-
Buccal mucosa neoplasm 0 trials · 2 incl. sub-types
2 sub-types
- Cheek mucosa cancer 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of buccal mucosa 0 trials Sub-types →
-
Gingival neoplasm 0 trials · 2 incl. sub-types
3 sub-types
- Gingival cancer 1 trial · 2 incl. sub-types Sub-types →
- Benign neoplasm of gum 0 trials Sub-types →
- Congenital epulis 0 trials
-
Neoplasm of floor of mouth 0 trials · 2 incl. sub-types
2 sub-types
- Malignant tumor of floor of mouth 0 trials · 2 incl. sub-types Sub-types →
- Benign neoplasm of floor of mouth 0 trials
-
Palatal neoplasm 0 trials · 2 incl. sub-types
4 sub-types
- Hard palate cancer 0 trials · 1 incl. sub-types Sub-types →
- Soft palate cancer 0 trials · 1 incl. sub-types Sub-types →
- Benign neoplasm of hard palate 0 trials
- Benign neoplasm of soft palate 0 trials
-
Head and neck paraganglioma 1 trial
4 sub-types
- Carotid body paraganglioma 0 trials Sub-types →
- Jugulotympanic paraganglioma 0 trials Sub-types →
- Tympanic paraganglioma 0 trials
- Vagus nerve paraganglioma 0 trials
-
Cavernous hemangioma of face 0 trials
1 sub-type
- Cavernous hemangioma of retina 0 trials
-
Epignathus 0 trials
-
Facial dermoid cyst 0 trials
2 sub-types
- Nasal dermoid cyst 0 trials
- Orbital dermoid cyst 0 trials
-
Gasserian ganglion meningioma 0 trials
-
Laryngeal neuroendocrine neoplasm 0 trials
1 sub-type
- Laryngeal small cell carcinoma 0 trials
-
Laryngotracheal angioma 0 trials
-
Lipoma of face 0 trials
1 sub-type
- Lipoma of the conjunctiva 0 trials
-
Nasal ganglioglioma 0 trials
-
Nasal glial heterotopia 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1546 trials in this tab.
-
Can a triple drug combo before surgery stop oral cancer from returning?
Cure Recruiting nowResearchers are testing whether giving tislelizumab, albumin paclitaxel, and cisplatin before surgery, followed by standard treatment, works better than standard treatment alone for people with locally advanced oral squamous cell carcinoma. The trial enrolls 134 participants with…
Phase 3 • Sponsor: Lai-ping Zhong • Aim: Cure
Last updated Sep 21, 2026 21:00 UTC
-
Off-the-Shelf immune cells target solid tumors
Cure Recruiting nowResearchers are testing a new cell therapy called CAR001 in adults with solid tumors that have come back or stopped responding to standard treatment. CAR001 uses donor gamma-delta T cells engineered with a chimeric antigen receptor to recognize and attack cancer cells. The trial …
Phase 1/2 • Sponsor: Ever Supreme Bio Technology Co., Ltd. • Aim: Cure
Last updated Sep 11, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Vaccine Recruiting nowThis study tests a personalized vaccine created from a patient's own immune cells (dendritic cells) that are trained to attack unique markers on their tumor. It is for people with advanced solid tumors who have not responded to standard treatments. The main goal is to check safet…
Sponsor: Fudan University • Aim: Vaccine
Last updated Jun 27, 2026 12:04 UTC
-
New injection fights head and neck cancer from the inside
Disease control Recruiting nowThis early-stage trial tests a new treatment called VLPONC-01, which is injected directly into head and neck tumors. It delivers a substance (IL-12) that may help the immune system attack the cancer. Some participants will also receive the immunotherapy drug pembrolizumab. The ma…
Phase 1 • Sponsor: VLP Therapeutics • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Can early oral cancer patients skip neck surgery?
Disease control Recruiting nowResearchers compare two ways to manage the neck in people with early oral squamous cell carcinoma, a cancer that has not spread to lymph nodes. One group has surgery to remove the primary tumor only, then regular checkups with imaging to watch for lymph node spread. The other gro…
Sponsor: Huashan Hospital • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New hope for advanced cancers: experimental drug ACR-2316 enters first human trial
Disease control Recruiting nowThis early-stage trial tests an experimental drug called ACR-2316 in 100 people with advanced solid tumors that have spread or come back. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. It is for patients who have had up to 3 pr…
Phase 1/2 • Sponsor: Acrivon Therapeutics • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Targeted pill takes on rare skull base cancers
Disease control Recruiting nowThis phase 2 trial tests enasidenib, a daily pill that targets the IDH2 gene mutation, in 40 adults with rare cancers of the nasal cavity or skull base that have spread or come back. Participants take the drug once daily in 28-day cycles, and researchers will track how long the c…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Experimental pill HG146 put to the test against rare head and neck cancer
Disease control Recruiting nowResearchers are testing an experimental drug called HG146 in people with adenoid cystic carcinoma that has come back or spread. The trial enrolls about 140 adults and gives them HG146 capsules to see if the drug can shrink tumors or slow cancer growth. Doctors track tumor respons…
Phase 2 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase 1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New drug BL-B01D1 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…
Phase 1 • Sponsor: SystImmune Inc. • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
New STING agonist drug enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Can a new drug rally the immune system against Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial tests an experimental medicine called BI 3822971 in adults with advanced or metastatic solid cancers, such as lung, head and neck, breast, esophageal, bladder, vulvar, or cervical cancer, who have no standard treatment options left. The goal is to find out …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 21, 2026 21:00 UTC
-
Experimental biologic AWT020 put to the test in Hard-to-Treat cancers
Disease control Recruiting nowResearchers are testing an experimental biologic called AWT020 in adults with advanced solid tumors that have worsened after at least one standard treatment. The phase 1 trial gives AWT020 every three weeks at increasing dose levels to find the highest dose people can tolerate an…
Phase 1 • Sponsor: Anwita Biosciences • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis study tests whether a combination of drugs (pembrolizumab and N-803, with or without special immune cells called PD-L1 t-haNK cells) can help shrink head and neck cancers before surgery. About 40 adults with untreated, HPV-negative head and neck cancer will receive these tre…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug HMPL-A580 enters human trials
Disease control Recruiting nowThis early-phase trial tests an experimental drug called HMPL-A580 in 186 adults with advanced or metastatic solid tumors that cannot be removed by surgery. The study aims to find a safe dose and check for early signs that the drug shrinks tumors. It is currently recruiting parti…
Phase 1/2 • Sponsor: Hutchmed • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New pill NP-101 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an oral drug called NP-101 in 35 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and side effects, with a secondary look at whether the drug can shrink tumors. Because it is a Pha…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Poop pills? stool transplants may ease immunotherapy side effects
Disease control Recruiting nowThis early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…
Phase 1/2 • Sponsor: BioInvent International AB • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can a new drug ASP388B take on advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ASP388B, given alone or alongside standard cancer therapies, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second tests that dose in…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New bispecific antibody D3L-002 enters first human trial for Hard-to-Treat cancers
Disease control Recruiting nowThis Phase 1 trial tests D3L-002, a new drug that targets two immune checkpoints (TIGIT and PVRIG) to help the immune system fight cancer. It is for 24 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the r…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug cocktail aims to outsmart advanced cancers
Disease control Recruiting nowThis early-phase trial is testing whether combining the drug talazoparib with one of three other drugs (palbociclib, axitinib, or crizotinib) can safely help control advanced solid tumors that have spread. Talazoparib blocks cancer cells from repairing their DNA, while the other …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo therapy aims to tackle rare nasal cancer
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy can shrink advanced squamous cell cancers of the nasal cavity and sinuses better than chemotherapy alone. About 35 adults with newly diagnosed, untreated stage II to IVb disease …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New drug DS3610a enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called DS3610a in about 70 adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can help control the cancer. P…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug YL217 enters first human tests
Disease control Recruiting nowThis early-phase study is testing an experimental drug called YL217 in 220 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and look for early signs that the drug can shrink tumors. Participa…
Phase 1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis early-phase study is testing an experimental drug called 177Lu-IM-3050 in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. About 105 participants will receive the drug to s…
Phase 1 • Sponsor: Immunome, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests a new drug, TER-2013, in people with advanced solid tumors (like breast, ovarian, or lung cancer) that have specific genetic changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe and can shrink tumors. About 205 participants will receive th…
Phase 1/2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase 2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail targets Virus-Linked cancers in early trial
Disease control Recruiting nowThis phase 1 study tests a combination of two drugs, pomalidomide (a pill) and nivolumab (an infusion), in adults with cancers caused by viruses like Epstein-Barr, HPV, or hepatitis. The goal is to find a safe dose and see if the drugs can shrink tumors. Up to 58 people with Kapo…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
First-in-Human trial asks whether HG381 is safe and tolerable in advanced solid tumors
Disease control Recruiting nowResearchers are running a first-in-human Phase 1 trial of HG381, an experimental drug given by intravenous injection, in adults with advanced solid tumors that have worsened after available treatments. The study aims to find out how safe and tolerable the drug is, how the body pr…
Phase 1 • Sponsor: HitGen Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New cancer drug GI-108 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new drug called GI-108 in people with advanced or metastatic solid tumors, including lung, head and neck, pancreatic, and kidney cancers. The drug is designed to boost the immune system's ability to fight cancer. The trial will first find the safest dose, then …
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Exercise after cancer therapy: a new way to gauge prognosis?
Disease control Recruiting nowThis trial tests whether a high-intensity interval training (HIIT) program can help head and neck cancer patients maintain or improve muscle mass after chemoradiotherapy. Researchers will use imaging and blood tests to see if changes in muscle and inflammation markers can predict…
Sponsor: Chang Gung Memorial Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New combo therapy takes on advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called N-3C01, given alone or with an immunotherapy, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety, find the right dose, and see if the combination shrinks tumors. About 114 a…
Phase 1/2 • Sponsor: Hefei Xinzhu Biological Technology Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, br…
Phase 1 • Sponsor: Aktis Oncology, Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Could immunotherapy replace chemo in nasopharyngeal cancer?
Disease control Recruiting nowThis phase III trial tests whether adding the immunotherapy drug serplulimab to standard induction chemotherapy can allow patients with advanced nasopharyngeal cancer to skip concurrent chemotherapy during radiation. The study plans to enroll 456 adults aged 18-65 with stage II-I…
Phase 3 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a sixth day of radiation beat cancer recurrence?
Disease control Recruiting nowThis study compares two radiotherapy schedules for people with head and neck cancer who begin radiation more than 6 weeks after surgery. One group gets standard treatment (5 days a week), the other gets an accelerated schedule (6 days a week). The goal is to see if the faster sch…
Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug cocktail aims to fight Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…
Phase 1/2 • Sponsor: Wigen Biomedicine Technology (Shanghai) Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental vaccine aims to boost immune attack on head and neck tumors
Disease control Recruiting nowThis phase 2 trial tests a new approach for patients with resectable head and neck squamous cell carcinoma. It combines an engineered mitochondrial vaccine (IMP3-Mito) with an immune checkpoint inhibitor (PD-1 inhibitor) given before and after surgery. The goal is to improve the …
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Experimental injection SHR-7787 put to the test against advanced solid tumors
Disease control Recruiting nowResearchers are testing an experimental injection called SHR-7787 in adults with advanced solid tumors that cannot be removed by surgery or have spread. The trial aims to find a safe dose, measure how the body processes the drug, and look for early signs that it shrinks tumors. P…
Phase 1/2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Engineered immune cells take on recurrent head and neck cancer
Disease control Recruiting nowThis study tests a new treatment called iC9-CAR.CSPG4 T cells for people with head and neck cancer that has come back after standard treatments. The therapy uses a patient's own immune cells, modified in a lab to better recognize and attack cancer cells. The main goals are to fin…
Phase 1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill shrink Hard-to-Treat ovarian tumors?
Disease control Recruiting nowResearchers are testing a new oral drug called DC05F01 in adults with recurrent ovarian cancer and other advanced solid tumors that have worsened after standard treatment. The trial aims to see how well the drug shrinks tumors, how long it keeps cancer from growing, and what side…
Phase 1/2 • Sponsor: Heronova Pharmaceuticals • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers in early human trial
Disease control Recruiting nowThis study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…
Phase 1 • Sponsor: Accent Therapeutics • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets MTAP deletion
Disease control Recruiting nowThis phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.
Phase 2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers: early trial recruits 554 patients
Disease control Recruiting nowThis study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…
Phase 1/2 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
DNA-Guided immunotherapy trial aims to match drug to tumor
Disease control Recruiting nowThis study tests the immunotherapy drug atezolizumab in 200 people with advanced solid tumors (breast, lung, GI, and others). Researchers use each person's tumor DNA to see if it predicts a response. Participants get the same dose every 3 weeks. The goal is to see if DNA analysis…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill shows promise in early trial for tough cancers
Disease control Recruiting nowThis early-stage trial is testing a new oral drug called ISM6331 in 100 adults with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug can shrink tumors. Partic…
Phase 1/2 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New pill takes on brain tumors and metastases in early trial
Disease control Recruiting nowThis study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a smart drug deliver a toxic payload directly to cancer cells?
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called TQB6426 in people with advanced cancers that have not responded to other treatments. TQB6426 is designed to seek out a protein called GPC3 on cancer cells and deliver a chemotherapy-like payload directly to them. The s…
Phase 1 • Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can a pill combo keep uveal melanoma from coming back?
Disease control Recruiting nowThis phase 3 trial tests whether taking darovasertib and crizotinib after standard treatment can delay or prevent uveal melanoma from returning. The study enrolls adults with high-risk, non-metastatic uveal melanoma who have completed local therapy such as surgery or radiation. P…
Phase 3 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a yeast vaccine stop Cancer's return?
Disease control Recruiting nowThis study tests a vaccine made from candida (a type of yeast) to see if it can reduce the risk of head and neck cancer coming back. About 100 adults who have finished cancer treatment and are currently cancer-free will receive either the vaccine or a placebo over two years. The …
Phase 2 • Sponsor: University of Arkansas • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can steroids help cancer patients resume a promising therapy?
Disease control Recruiting nowThis study has two parts. Part A tests whether cancer patients who stopped a type of immunotherapy (checkpoint inhibitors) due to side effects can safely restart treatment with durvalumab, given alongside the steroid prednisone to reduce the risk of side effects returning. Part B…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug shows promise against rare eye cancer before liver surgery
Disease control Recruiting nowThis phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can …
Phase 2 • Sponsor: Grupo Español Multidisciplinar de Melanoma • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Cancer patients on targeted therapy get extended safety monitoring
Disease control Recruiting nowThis study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug DXP-106 enters early human testing
Disease control Recruiting nowThis early-stage trial tests a new drug called DXP-106 in 54 people with advanced solid tumors that have not responded to standard treatments. The study aims to find safe doses and see if DXP-106 works better when given alone or with chemotherapy. Participants receive the drug by…
Phase 1 • Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Immune cells harvested from tumors could fight advanced cancers
Disease control Recruiting nowThis early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug QLC5508 enters first human safety tests
Disease control Recruiting nowThis early-stage study tests a new drug called QLC5508 in 48 adults with advanced solid tumors that have stopped responding to treatment. The main goals are to check if the drug affects heart rhythm, compare two versions of the drug, and see how it interacts with other medicines.…
Phase 1 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New radiation technique may improve cancer control in advanced head and neck cancer
Disease control Recruiting nowThis study compares a newer, precise radiation method called stereotactic body radiotherapy (SBRT) with standard radiation therapy for people with advanced head and neck cancer who cannot have curative treatment. About 196 adults will be randomly assigned to one of the two radiat…
Phase 3 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets rare cancer mutation in early trial
Disease control Recruiting nowThis study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…
Phase 1/2 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cell therapy trial hopes to tackle tough cancers
Disease control Recruiting nowThis early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…
Phase 1/2 • Sponsor: Second Life Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug BI 3810944 enters first human tests
Disease control Recruiting nowThis early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase 1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug ART6043 enters human trials for advanced tumors
Disease control Recruiting nowThis study tests a new oral drug called ART6043, alone or with another drug (olaparib), in 181 people with advanced or metastatic solid tumors. The goal is to check safety, how the body processes the drug, and whether it can slow tumor growth. It is an early-stage trial, so the m…
Phase 1/2 • Sponsor: Artios Pharma Ltd • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Blood test may let some throat cancer patients skip radiation after surgery
Disease control Recruiting nowThis study is for people with HPV-related throat cancer who have surgery to remove the tumor. Normally, some patients also get radiation afterward to lower the risk of cancer coming back. This trial tests whether it's safe to skip that radiation if a blood test two weeks after su…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: first human trial of BGB-58067 begins
Disease control Recruiting nowThis early-stage trial is testing a new drug called BGB-58067, alone or with other cancer treatments, in people with advanced solid tumors that have a specific genetic change (MTAP deficiency). The study aims to find the safest dose and see if the drug can shrink tumors. About 52…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo aims to boost chemoradiation for head and neck cancer
Disease control Recruiting nowThis early-phase study tests whether adding the experimental drug ipatasertib to standard chemotherapy and radiation is safe and effective for people with advanced head and neck cancer. Ipatasertib may help stop cancer cell growth. About 46 participants will receive the combinati…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…
Phase 1/2 • Sponsor: GI Innovation, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
A balloon that coats heart arteries in drug, no stent left behind
Disease control Recruiting nowResearchers are testing whether a balloon catheter coated with the drug sirolimus can safely open narrowed coronary arteries in adults with heart disease. The balloon inflates to press the drug into the artery wall, aiming to keep the vessel open without leaving a permanent stent…
Sponsor: Tonic Medical, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study is testing a new drug called BGB-26808, either alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. About 217 partici…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New cancer drug targets two proteins at once in early trial
Disease control Recruiting nowThis early-phase trial is testing a new drug called BG-C0902 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to two proteins (EGFR and MET) often found on cancer cells and deliver a toxic payload directly to them…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a gene test guide better treatment for head and neck cancer survivors?
Disease control Recruiting nowThis study compares two treatments after surgery for stage III-IVA head and neck cancer: radiation alone versus radiation plus the chemotherapy drug cisplatin. The goal is to see which approach better prevents the cancer from returning, especially in patients with certain TP53 ge…
Phase 2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a radioactive 'Smart Bomb' target tough tumors?
Disease control Recruiting nowResearchers are testing an experimental radioactive drug called 177Lu-FAP-VG11 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to seek out and attach to a protein called FAP, which is found on many tumor cells. This early …
Early phase 1 • Sponsor: Shandong Cancer Hospital and Institute • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests a drug called becotatug vedotin, given alone or with immune-boosting drugs (penpulimab or ivonescimab), before surgery for head and neck cancer. The goal is to see if these treatments can shrink tumors or even make them disappear completely. The study inv…
Phase 2 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can an experimental pill slow advanced solid tumors? a phase 1 trial puts HW221043 to the test.
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called HW221043 in adults with advanced solid tumors who have no standard treatment options left. The study has two parts: first, finding a safe dose, then expanding to see if the drug can shrink tumors or slow their gro…
Phase 1 • Sponsor: Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Experimental biologic M1-c6v1 put to the test in Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are testing an experimental intravenous biologic called M1-c6v1 in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The Phase I trial gives escalating doses to a small group of participants to check safety, find th…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Two-Drug combo targets Hard-to-Treat salivary gland tumors
Disease control Recruiting nowResearchers are testing whether combining abiraterone and dalpiciclib can shrink recurrent or metastatic salivary gland cancer that is AR-positive and HER-2-negative. The trial enrolls up to 36 adults who have no curative surgery or radiation options. Participants take both drugs…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immunotherapy combo shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called volrustomig, either alone or with chemotherapy, in people with advanced cervical, head and neck, esophageal, or mesothelioma cancers. The study aims to see if the drug can shrink tumors and how safe it is. About 257 partic…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New 'seek and destroy' therapy for metastatic cancer enters human testing
Disease control Recruiting nowThis early-stage study tests a two-part system to find and treat metastatic cancer. First, a radioactive tracer is used to spot tumors on a PET scan. Then, a similar radioactive drug is given to deliver radiation directly to the cancer cells. The goal is to see if this approach i…
Phase 1 • Sponsor: University of California, Davis • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Phase 1/2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug MK-8294 tested in patients with advanced cancers
Disease control Recruiting nowThis early-phase study tests a new targeted therapy called MK-8294 in people with advanced solid tumors that have spread. The main goals are to check the drug's safety, see if people can tolerate it, and find the highest safe dose. About 67 participants will receive the drug, and…
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug SKB118 aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis study tests a new drug called SKB118 in 332 adults with advanced solid tumors that have not responded to standard treatments. The drug is given by IV every three weeks. The trial will first find the safest dose, then check if it can shrink tumors. It is currently not recruit…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
Can common drugs stop radiation damage? new trial aims to prevent lymphedema
Disease control Recruiting nowThis phase 2 trial tests whether pravastatin (a cholesterol drug) or a combination of pentoxifylline and vitamin E can prevent lymphedema and fibrosis (swelling and scarring) caused by radiation therapy in head and neck cancer patients. About 295 adults with oropharyngeal cancer …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control Recruiting nowThis study is testing a new experimental drug called BG-75098, given alone or with other medicines, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tum…
Phase 1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Experimental biological therapy VRT106 put to the test in advanced solid tumors
Disease control Recruiting nowResearchers are running a Phase I trial of VRT106, an experimental biological therapy given by intravenous drip, in adults with locally advanced or metastatic solid tumors that have not responded to standard treatment. The trial enrolls about 12 people aged 18 to 75. It aims to f…
Phase 1 • Sponsor: Guangzhou Virotech Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New cancer drug KK2269 enters first human tests
Disease control Recruiting nowThis early-stage trial tests the safety of a new drug called KK2269, given alone or with chemotherapy (docetaxel), in adults with advanced solid tumors that have no standard treatment options. About 101 participants will take part. The study has two parts: first testing KK2269 al…
Phase 1 • Sponsor: Kyowa Kirin Co., Ltd. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug FORX-428 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …
Phase 1 • Sponsor: FoRx Therapeutics AG • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Triple-Drug attack on EGFR-Positive head and neck tumors
Disease control Recruiting nowResearchers are testing whether giving becotatug vedotin, pucotenlimab, and cisplatin before surgery can shrink locally advanced EGFR-positive head and neck squamous cell carcinoma. The trial enrolls 40 adults with stage III or IV disease who have not yet received treatment. Part…
Phase 2 • Sponsor: Xuekui Liu • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New antibody EPI-326 enters first human trials for tough cancers
Disease control Recruiting nowThis early-phase study tests a new drug called EPI-326 in about 110 people with advanced lung or head & neck cancers that have specific EGFR mutations. The drug is a bispecific antibody designed to target cancer cells more precisely. The main goals are to check safety, find the r…
Phase 1 • Sponsor: EpiBiologics • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo therapy aims to extend life in hard-to-treat head and neck cancer
Disease control Recruiting nowThis phase 3 trial tests whether giving re-radiation with chemotherapy followed by the immunotherapy drug pembrolizumab can help people with recurrent head and neck cancer live longer compared to standard pembrolizumab alone or with chemotherapy. The study includes 214 adults who…
Phase 3 • Sponsor: Universität des Saarlandes • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for advanced cancer? early trial tests MK-3120
Disease control Recruiting nowThis study is testing a new drug called MK-3120 in people with advanced solid tumors that have spread and cannot be removed by surgery. The main goal is to see if the drug is safe and tolerable. About 270 participants will receive the drug by IV infusion. The study also looks at …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Alpha radiation targets tumors in new cancer trial
Disease control Recruiting nowResearchers are testing two investigational radiopharmaceuticals in adults with advanced solid tumors, including colorectal, pancreatic, biliary tract, gastric, esophageal, and head and neck cancers. First, participants receive SKL35502, an imaging agent that highlights tumors ca…
Phase 1 • Sponsor: SK Life Science, Inc. • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase 1/2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New combo therapy aims to shrink advanced tumors
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug durvalumab to standard chemotherapy can help control advanced solid tumors that have spread. About 115 adults whose cancer has worsened after at least one prior treatment will receive the combination. The main goal is to chec…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called SA53-OS in people with advanced or metastatic solid tumors that have not responded to standard treatments. The drug works by blocking a protein called MDM2, which may help slow or stop tumor growth. The study has two parts: first,…
Phase 1/2 • Sponsor: Lamassu Bio Inc • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for rare eye cancer: drug targets tumors with DNA tracking
Disease control Recruiting nowThis study tests a drug called tebentafusp in people with a specific type of advanced eye cancer (uveal melanoma) that has spread to other parts of the body. The drug is designed to help the immune system attack cancer cells. Researchers will also use a blood test to measure tumo…
Phase 2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug TAK-505 enters first human trials
Disease control Recruiting nowThis study tests a new drug called TAK-505 in adults with advanced solid tumors that cannot be removed by surgery. The main goals are to check safety, find the best dose, and see if the drug can shrink or slow cancer growth. About 151 people with certain cancers, such as stomach,…
Phase 1/2 • Sponsor: Takeda • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SGT003 put to the test against Hard-to-Treat solid tumors
Disease control Recruiting nowResearchers are running a phase I/IIa trial of SGT003, an experimental intravenous drug, in adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: a dose-escalation phase to find a safe dose and a dose-expansion phase to look fo…
Phase 1/2 • Sponsor: Beijing Sungen Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis phase 1 trial is testing a new drug called ADCE-T02 in people with advanced solid tumors that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to target a protein called tissue factor found on many cancer cells. The main goals are to…
Phase 1 • Sponsor: Adcendo ApS • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug SKB571 takes on recurrent head and neck cancer
Disease control Recruiting nowThis study tests a new drug called SKB571 in 30 adults with head and neck cancer that has returned or spread and cannot be removed by surgery. The goal is to see if the drug can shrink tumors and how safe it is. Participants will receive the drug and be monitored for response and…
Phase 2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New cancer drug AGX101 enters human trials for advanced tumors
Disease control Recruiting nowThis early-stage trial tests AGX101, a drug that delivers chemotherapy directly to cancer cells by targeting a protein called TM4SF1. About 80 adults with advanced solid tumors (like breast, prostate, or pancreatic cancer) who have run out of standard options will receive the dru…
Phase 1 • Sponsor: Angiex, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug GEN1119 aims to fight solid tumors that resist standard care
Disease control Recruiting nowThis trial investigates a new drug called GEN1119 for people with certain solid tumors that have not improved with standard treatments or for whom no standard treatment exists. The study is divided into parts: first, to find safe and effective doses, then to test those doses in m…
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
BioNTech launches first human test of BNT317 against advanced cancers
Disease control Recruiting nowThis early-phase trial is testing a new experimental drug, BNT317, in 39 people with advanced solid tumors who have run out of standard treatment options. The main goal is to check the drug's safety, find the right dose, and see how the body handles it. It is too soon to know if …
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat breast cancers
Disease control Recruiting nowThis early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cancer drug FID-022 enters first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called FID-022 in 24 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. The drug contains two active components, including irinotecan, which is …
Phase 1 • Sponsor: Fulgent Pharma LLC. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase 1/2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new drug combo slow advanced head and neck cancer?
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called ficerafusp alfa, which targets two proteins that help tumors grow, when given with the immunotherapy pembrolizumab. The study enrolls adults with recurrent or metastatic head and neck squamous cell carcinoma that has not been t…
Phase 2 • Sponsor: Bicara Therapeutics • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New trial aims to stop oral lesions from turning into cancer
Disease control Recruiting nowThis study looks at the best way to treat people with p53-mutant oral dysplasia (abnormal cells in the mouth) and early-stage oral cancer. About 636 adults will be placed into three groups based on their diagnosis and receive either monitoring, surgery, or surgery plus neck disse…
Sponsor: University of British Columbia • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a new radiation approach tackle recurrent head and neck cancer?
Disease control Recruiting nowThis phase II trial tests a new type of radiation therapy called accelerator-based boron neutron capture therapy (AB-BNCT) for people with head and neck cancer that has returned after prior treatment. The therapy combines a boron-containing drug (NBB-001) with a tracer (NBB-002) …
Phase 2 • Sponsor: Neuboron Bio-SciTech Co., Ltd. • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New radioactive drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new radioactive drug, 177Lu-INN805, in 10 people with advanced solid tumors (like head & neck, lung, breast, or sarcoma) that haven't responded to standard treatments. The main goals are to find a safe dose and check for side effects. Researchers wi…
Early phase 1 • Sponsor: FindCure Biosciences (ZhongShan) Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New Antibody-Drug conjugate targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SI-B036, a bispecific antibody designed to fight advanced gastrointestinal and other solid tumors. The study involves about 16 adults with tumors that have spread or cannot be removed. Researchers aim to find a safe dose and see if t…
Phase 1 • Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a Triple-Drug attack stop eye lymphoma in its tracks?
Disease control Recruiting nowThis phase II trial is testing a combination of three drugs—zanubrutinib, rituximab, and methotrexate—given through the vein and directly into the eye, for people newly diagnosed with primary intraocular lymphoma, a rare cancer of the eye. The goal is to see if this regimen can i…
Phase 2 • Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug AVZO-1418 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AVZO-1418 in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if it shrinks tumors. About 480 adults will take part, receiving the drug alone or with other treatments.
Phase 1/2 • Sponsor: Avenzo Therapeutics, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Immunotherapy boost before surgery may improve sinonasal cancer outcomes
Disease control Recruiting nowThis phase 2 trial tests whether adding the immunotherapy drug cemiplimab to standard chemotherapy before surgery helps people with sinonasal squamous cell carcinoma. About 108 participants will be randomly assigned to receive either chemo alone or chemo plus cemiplimab before th…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new pill shrink advanced solid tumors?
Disease control Recruiting nowThis trial tests an experimental drug called ODM-216 in adults with advanced solid tumors, which are cancers that have spread or cannot be removed by surgery. The study has two parts: the first finds a safe dose, and the second checks how well that dose fights the cancer. Researc…
Phase 1/2 • Sponsor: Orion Corporation, Orion Pharma • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IMGS-001 enters human trials
Disease control Recruiting nowThis early-stage study tests an experimental drug called IMGS-001 in about 105 people with advanced solid tumors that have come back or not improved after standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. The study has two parts: first, t…
Phase 1 • Sponsor: ImmunoGenesis • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New smart drug targets tough cancers in early trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called PF-08046876 in about 310 adults with advanced cancers of the bladder, lung, head and neck, esophagus, or pancreas that have not responded to standard treatments. The drug is a type of 'antibody drug conjugate' designed to s…
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new targeted drug outperform standard therapy for advanced head and neck cancer?
Disease control Recruiting nowThis phase III trial compares an experimental drug called MRG003 with two standard treatments, cetuximab and methotrexate, in adults with recurrent or metastatic squamous cell carcinoma of the head and neck. Participants must have already tried and failed both a PD-1/PD-L1 inhibi…
Phase 3 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cell therapy targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…
Phase 1 • Sponsor: Zelluna Immunotherapy AS • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with brain spread
Disease control Recruiting nowThis early-phase study tests a daily oral drug called CGT4255 in 100 adults with advanced solid tumors that have ERBB2 genetic changes or HER2 overexpression. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors, including in the brain. The …
Phase 1 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug aims to stop head and neck cancer from returning
Disease control Recruiting nowThis large Phase 3 trial tests whether an experimental immunotherapy drug called volrustomig can help prevent cancer from returning in people with locally advanced head and neck cancer who have finished chemoradiation. About 1,145 participants will either receive volrustomig or b…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug SKB565 aims to fight advanced solid tumors
Disease control Recruiting nowThis study tests an experimental drug called SKB565 in 180 adults with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The trial has three stages to find the safest dose, check how the drug moves through the body, and see if it shrinks tum…
Phase 1/2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets HER2 cancers in promising trial
Disease control Recruiting nowThis Phase 2 trial tests an oral drug called BAY 2927088 (sevabertinib) in about 111 adults with advanced solid tumors that have HER2 gene mutations. The drug aims to block the abnormal HER2 protein and stop cancer growth. Participants take a 20 mg tablet daily in 3-week cycles u…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug IDP-001 takes on advanced cancers in early trial
Disease control Recruiting nowThis study tests an experimental drug called IDP-001 in people with advanced or metastatic solid tumors, including certain lung, head and neck, and other cancers. The trial has two phases: first to check safety and find the right dose, then to see if the drug can shrink tumors. A…
Phase 1/2 • Sponsor: InduPro, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug VBC101 targets tough cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called VBC101 in people with advanced solid tumors that have stopped responding to standard treatments. The drug is designed to attach to two cancer-related targets (EGFR and cMET) and deliver a toxic payload directly to cancer cells. The s…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New pill targets rare cancer gene in 30-Patient trial
Disease control Recruiting nowThis phase 2 trial tests an oral drug called lirafugratinib in 30 adults with advanced solid tumors (excluding bile duct cancer) that have an FGFR2 gene fusion or rearrangement. Participants take the drug regularly and visit the clinic for checkups. The main goal is to see if the…
Phase 2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for tough cancers: experimental drug IPN01203 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01203 in about 102 adults with advanced solid tumors that have spread and stopped responding to immunotherapy. The trial has two parts: first, finding a safe dose, then testing low versus high doses to see if the drug can shrink tumors. Parti…
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Dental checkups every 3 months may save cancer Survivors' teeth and smiles
Disease control Recruiting nowThis study tests whether extra dental care every three months for three years can prevent or reduce late side effects like dry mouth, cavities, and jaw stiffness in head and neck cancer survivors. 300 adults who completed radiation or chemoradiation will either get this extra sup…
Sponsor: Uppsala University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Radiation alone vs. chemoradiation: a Head-to-Head test in head and neck cancer
Disease control Recruiting nowThis trial compares two treatments for advanced head and neck squamous cell carcinoma. One group receives standard chemoradiation, which combines radiation with the chemotherapy drug cisplatin. The other group receives hyperfractionated radiation, which delivers a higher total do…
Sponsor: King Hussein Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
BioNTech launches trial of BNT326 for advanced cancers
Disease control Recruiting nowThis study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…
Phase 1/2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug targets hard-to-treat cancers with missing MTAP gene
Disease control Recruiting nowThis early-stage trial tests an experimental drug called MRTX1719 in adults with advanced solid tumors that have a missing MTAP gene. The study aims to find a safe dose and see if the drug can shrink tumors or slow their growth. About 336 participants with cancers like mesothelio…
Phase 1 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo therapy aims to shrink head and neck tumors
Disease control Recruiting nowThis phase 2 study tests whether adding the experimental drug VS-101 to standard chemoradiotherapy helps shrink tumors in 30 adults with head and neck cancer. Participants are randomly assigned to receive VS-101 plus chemoradiation or chemoradiation alone. The main goal is to see…
Phase 2 • Sponsor: VSPharmTech Co.,Ltd. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New combo injection targets Hard-to-Treat head and neck tumors
Disease control Recruiting nowThis early-phase trial is testing a new approach for people with head and neck cancer that has returned or spread after standard chemotherapy. The treatment combines a gene therapy injection (EDS01) given directly into a tumor with an immunotherapy drug (toripalimab) given throug…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a platform trial match the right drug combo to each tumor?
Disease control Recruiting nowThis phase I/II platform trial tests several drug combinations, including evorpacept, trastuzumab deruxtecan, zanidatamab, tucatinib, and TTX-MC138, in people with advanced solid tumors, especially metastatic breast cancer. The goal is to find safe and promising regimens that cou…
Phase 1/2 • Sponsor: QuantumLeap Healthcare Collaborative • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug duo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called PYX-201 combined with pembrolizumab in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the combination can shrink tumors. About 220 adults with certain cancers like head an…
Phase 1/2 • Sponsor: Pyxis Oncology, Inc • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New hope for advanced cancers? first human trial of DS5361b begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS5361b, alone or with another drug (pembrolizumab), in adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can heat boost chemo? early trial tests thermotherapy for head and neck cancer
Disease control Recruiting nowThis early-phase trial tests whether adding mild heat therapy (thermotherapy) to standard chemoradiation is safe and tolerable for people with advanced head and neck cancer. The heat, applied once a week, aims to make the cancer more sensitive to treatment. The study includes two…
Phase 1 • Sponsor: Erasmus Medical Center • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug NEOK001 targets Hard-to-Treat cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests a new drug called NEOK001 in people with advanced solid tumors that have stopped responding to standard treatments. NEOK001 is designed to deliver a cancer-killing agent directly to tumor cells by targeting two specific proteins. The study will first …
Phase 1 • Sponsor: NEOK Bio, Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New CAR T-Cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests an experimental therapy called FT836, a ready-made CAR T-cell treatment, in people with advanced solid tumors like lung, colorectal, breast, ovarian, endometrial, or head and neck cancers that have not responded to prior treatments. The main goals are…
Phase 1 • Sponsor: Fate Therapeutics • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can your Cancer's genes pick the right drug? TAPUR study aims to find out
Disease control Recruiting nowThe TAPUR study is testing a wide range of targeted cancer drugs in people with advanced solid tumors, lymphoma, or multiple myeloma whose tumors have specific genetic changes. The goal is to see if matching drugs to these genetic variants can shrink tumors or stop them from grow…
Phase 2 • Sponsor: American Society of Clinical Oncology • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug IMA402 targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMA402 in people with advanced solid tumors that have come back or not responded to treatment. IMA402 is designed to help the immune system attack cancer cells. The trial will check if the drug is safe and whether it can shrink tumors.
Phase 1/2 • Sponsor: Immatics Biotechnologies GmbH • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug targets two cancer proteins in advanced tumors
Disease control Recruiting nowThis trial tests a new drug called VBC108 in people with advanced solid tumors that have not responded to standard treatments. VBC108 is designed to attach to two specific proteins (CLDN18.2 and CDH17) found on some cancer cells and deliver a toxic payload to kill them. The study…
Phase 1/2 • Sponsor: VelaVigo Bio Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New combo therapy aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase II trial is testing whether combining low-dose radiotherapy with the immunotherapy drug Toripalimab before surgery can improve outcomes for people with advanced head and neck squamous cell carcinoma. About 22 participants will receive two cycles of the combination, the…
Phase 2 • Sponsor: Rui You • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug JNJ-95437446 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called JNJ-95437446 in people with advanced solid tumors, including colorectal cancer, that have not responded to standard treatments. The study has two parts: first, finding a safe dose, and second, checking safety more closely in a larger…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug could protect children with cancer from chemo side effects
Disease control Recruiting nowThis study tests a drug called eflapegrastim in 40 children with solid tumors or lymphoma who are receiving chemotherapy. The drug aims to boost white blood cells and reduce the risk of serious infections. Researchers are checking how safe it is and how the body processes it.
Phase 2 • Sponsor: Spectrum Pharmaceuticals, Inc • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug IPN01195 enters human trials
Disease control Recruiting nowThis study tests a new drug called IPN01195 in about 85 adults with advanced solid tumors that have spread and no longer respond to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. Participants must have certain genetic changes in their …
Phase 1/2 • Sponsor: Ipsen • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can an immunotherapy combo shrink sinonasal tumors before surgery?
Disease control Recruiting nowThis trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can help people with sinonasal cancer, a rare cancer of the nasal cavity and sinuses. Participants receive toripalimab along with carboplatin and docetaxel, then undergo sur…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug cocktail aims to outdo chemo for tough throat cancer
Disease control Recruiting nowThis Phase 3 trial tests whether combining two drugs, MRG003 and pucotenlimab, works better than standard chemotherapy for people with nasopharyngeal cancer that has returned or spread. About 446 participants will be randomly assigned to receive either the new combo or one of thr…
Phase 3 • Sponsor: Lepu Biopharma Co., Ltd. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR t therapy takes on solid tumors in first human trial
Disease control Recruiting nowThis early-phase trial is testing a new immunotherapy called LEU011 for people with advanced solid tumors that have not responded to other treatments. LEU011 uses the patient's own immune cells, modified to better recognize and attack tumor cells. The study aims to find a safe do…
Phase 1/2 • Sponsor: Leucid Bio • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat kidney cancer
Disease control Recruiting nowThis early-stage study tests a new drug called casdatifan (AB521) alone or combined with other cancer drugs in people with advanced clear cell kidney cancer or other solid tumors. The main goals are to check safety and find the right dose. About 362 participants will take part.
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can proton radiation spare tonsil cancer patients from harsh side effects?
Disease control Recruiting nowThis trial tests whether proton therapy causes fewer side effects than standard photon radiation in people with early tonsil cancer. About 100 patients will be randomly assigned to receive one of the two radiation types, both aimed at curing the cancer. Researchers will track acu…
Sponsor: Lund University Hospital • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can a shorter, targeted radiation course tame throat cancer?
Disease control Recruiting nowThis phase III trial compares a new, shorter radiation approach to the standard 7-week chemoradiation for patients with HPV-positive oropharynx cancer. The experimental treatment uses a precise, high-dose radiation boost to the tumor followed by a reduced-dose chemoradiation cour…
Phase 3 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
MRI-Guided tweaks during radiation could spare throat cancer patients from swallowing woes
Disease control Recruiting nowThis phase II trial tests whether adapting radiation plans mid-treatment using MRI scans can reduce swallowing difficulties in patients with advanced oropharynx (throat) cancer. Participants receive standard chemoradiation, but half are randomly assigned to have their radiation p…
Phase 2 • Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New injection YKYY031 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called YKYY031 in 76 people with advanced solid tumors (like colorectal or pancreatic cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and get a first look at whether the …
Phase 1 • Sponsor: Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can freezing tumors offer a new lifeline for head and neck cancer?
Disease control Recruiting nowThis pilot study is investigating whether local cryotherapy—a procedure that freezes and destroys cancer cells—can control recurrent head and neck cancer in patients who have already received radiation therapy and cannot undergo surgery or further radiation. The trial will enroll…
Sponsor: University Hospital, Strasbourg, France • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in advanced tumors
Disease control Recruiting nowThis study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
Tailored radiation aims to shrink tumors, spare healthy tissue in nasopharyngeal cancer
Disease control Recruiting nowThis phase 3 trial tests whether a personalized radiation plan, which expands the treatment area based on each patient's tumor margins, can control nasopharyngeal cancer as well as the standard approach. The study includes 568 adults with newly diagnosed, non-metastatic disease. …
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
First-in-Class cancer drug targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental oral drug called VMD-102 in people with advanced solid tumors, including liver, lung, kidney, skin (uveal melanoma), and colorectal cancers that have not responded to standard treatments. The drug works by blocking a specific protein (PKC epsilon)…
Phase 1/2 • Sponsor: VM Discovery, Inc. • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase 2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase 1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new immune drug outsmart Hard-to-Treat tumors?
Disease control Recruiting nowThis trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …
Phase 1/2 • Sponsor: Marengo Therapeutics, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could skipping some neck radiation spare patients side effects?
Disease control Recruiting nowThis trial is testing whether it is safe to skip radiation to certain low-risk areas of the neck after surgery for head and neck cancer. The goal is to see if this approach can reduce side effects and preserve quality of life while still keeping the cancer from coming back. Parti…
Phase 2 • Sponsor: Institut Català d'Oncologia • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Less neck surgery may be just as effective for oral cancer with one affected node
Disease control Recruiting nowThis trial tests whether removing fewer lymph nodes from the neck (selective dissection, levels I-IV) works as well as the standard more extensive removal (modified dissection, levels I-V) in people with oral cancer that has spread to a single lymph node. The goal is to see if th…
Sponsor: Kolhapur Cancer Centre - Cancer Centers of America • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Less may be more: testing a gentler neck dissection for oral cancer
Disease control Recruiting nowThis trial compares two types of neck surgery for people with oral cancer that has not spread to lymph nodes. One surgery removes lymph nodes from levels I to IV, while the other removes only levels I to III. The goal is to see whether the less extensive surgery can control cance…
Sponsor: Kolhapur Cancer Centre - Cancer Centers of America • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can adding radiation boost immunotherapy against spread head and neck cancer?
Disease control Recruiting nowThis trial tests whether adding radiotherapy to the immunotherapy drug pembrolizumab (with or without chemotherapy) helps people with newly diagnosed head and neck cancer that has spread to other parts of the body. Participants receive either standard systemic treatment alone or …
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug duo aims to make inoperable sinus cancer removable
Disease control Recruiting nowThis phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted antibody-drug conjugate) and epirubicin (a standard chemo)—in 40 people with EGFR-positive, recurrent sinonasal adenoid cystic carcinoma that cannot be surgically removed. The goal is to shrink the …
Phase 2 • Sponsor: Eye & ENT Hospital of Fudan University • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can less be more? new trial aims to cut harsh side effects in HPV throat cancer treatment
Disease control Recruiting nowThis study is for people with HPV-related throat cancer. After surgery, patients receive lower-than-standard doses of radiation and sometimes chemotherapy, based on their risk level. The goal is to keep cancer from coming back while reducing side effects like weight loss. About 1…
Phase 2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can fewer Pre-Surgery doses of immunotherapy beat more in head and neck cancer?
Disease control Recruiting nowThis trial is investigating whether giving tislelizumab (an immunotherapy drug) combined with chemotherapy for 2 cycles before surgery works as well as 4 cycles in people with locally advanced head and neck squamous cell carcinoma. The study aims to find the best balance between …
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Could MRI replace CT for sharper cancer radiation planning?
Disease control Recruiting nowThis study investigates whether using magnetic resonance imaging (MRI) instead of standard CT scans to plan radiation therapy can improve treatment accuracy and reduce side effects. It enrolls adults with prostate, liver, or head and neck cancers who need radiation. Researchers w…
Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Promising drug cocktail aims to save voice boxes in throat cancer patients
Disease control Recruiting nowThis phase II trial tests two drugs—becotatug vedotin and pucotenlimab—given before surgery to people with advanced hypopharyngeal cancer. The goal is to shrink tumors enough to improve surgical outcomes and possibly preserve the voice box. About 52 participants will receive thre…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can engineered red blood cells fight cancer? new trial launches
Disease control Recruiting nowThis early-phase trial is testing an experimental therapy called WTX-212C, which uses specially engineered red blood cells to treat advanced solid tumors. The study will enroll 24 adults whose cancer has not responded to standard treatments. The main goal is to check safety and f…
Early phase 1 • Sponsor: Zhejiang Provincial People's Hospital • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase 2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Battle of the bands: which hemorrhoid treatment wins?
Disease control Recruiting nowThis study compares two standard treatments for bleeding internal hemorrhoids: hemorrhoidal artery embolization (HAE) and rubber band ligation (RBL). HAE uses a catheter to block blood flow to the hemorrhoid with tiny particles or coils, while RBL uses rubber bands to cut off cir…
Sponsor: Jessica K. Stewart, MD • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Zapping resistant tumors may extend life of cancer drugs
Disease control Recruiting nowThis study tests whether adding a precise local treatment—like focused radiation or ablation—can help people whose cancer has a few new or growing spots while on standard therapy. Participants continue their usual medication while the resistant tumors are treated directly. The go…
Sponsor: University of California, Davis • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New radiation approach aims to spare healthy tissue in sinus cancer treatment
Disease control Recruiting nowThis Phase 2 trial tests a new way to give radiation for sinus cancer after endoscopic surgery. Instead of radiating the whole sinus area, doctors will use a 'dose painting' technique that targets only the areas where cancer was found. The goal is to see if this reduces side effe…
Phase 2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New cocktail of old drugs takes on advanced cancers
Disease control Recruiting nowThis Phase 2 trial is testing a combination of three drugs—gemcitabine, mitomycin C, and thalidomide—given in low, frequent doses to people with advanced solid tumors that have not responded to prior treatments. The goal is to see if this approach can slow tumor growth and improv…
Phase 2 • Sponsor: Sarcoma Oncology Research Center, LLC • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with rare TP53 mutation
Disease control Recruiting nowThis study tests an experimental oral drug called NTS071 in adults with advanced solid tumors that have a specific change in the TP53 gene (Y220C mutation). The trial has two parts: first, finding a safe dose, and then checking if the drug can shrink tumors. About 220 people who …
Phase 1/2 • Sponsor: Nutshell Therapeutics (Shanghai) Co., LTD. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Custom 3D-Printed titanium implants could rebuild faces after injury or surgery
Disease control Recruiting nowThis study tests whether custom 3D-printed titanium implants can safely and effectively rebuild facial bones in 30 adults with defects from injury, cancer surgery, or birth conditions. Each implant is designed from CT scans to match the patient's unique anatomy. Researchers will …
Sponsor: Tishreen University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AB821 enters first human tests for advanced melanoma
Disease control Recruiting nowThis early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.
Phase 1 • Sponsor: Yale University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for hard-to-treat brain cancer: combo therapy enters trial
Disease control Recruiting nowThis study tests a new drug called epcoritamab, given with two other drugs (lenalidomide and rituximab), for people whose primary CNS lymphoma has returned or stopped responding to treatment. The goal is to see if this combination can shrink or control the cancer. About 60 adults…
Phase 2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug cocktail aims to stop head and neck cancer from coming back
Disease control Recruiting nowThis Phase II trial tests whether giving a combination of two drugs—Becotatug Vedotin (a targeted chemotherapy) and Pucotenlimab (an immunotherapy)—before and after surgery can improve outcomes for people with recurrent head and neck cancer that can still be removed. About 102 pa…
Phase 2 • Sponsor: Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New risk model may let some NPC patients avoid unnecessary chemo
Disease control Recruiting nowThis study tests a personalized approach for people with advanced nasopharyngeal cancer. After standard chemoradiation, some patients get extra therapy to prevent the cancer from returning. But this extra therapy can cause side effects. The trial uses a new risk model (RAIRI) to …
Phase 3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New hope for head and neck cancer: drug combo shows promise after standard treatment fails
Disease control Recruiting nowThis study tests whether adding a chemotherapy drug (paclitaxel) to a targeted therapy (cetuximab) works better than cetuximab alone for people with advanced head and neck cancer that has worsened after initial treatment. About 65 adults with recurrent or metastatic squamous cell…
Phase 2 • Sponsor: Grupo Español de Tratamiento de Tumores de Cabeza y Cuello • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Engineered immune cells take on Hard-to-Treat melanoma
Disease control Recruiting nowThis study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New experimental drug SIM0613 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called SIM0613 in about 294 adults with advanced solid tumors that have worsened after standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. The main goals are safety and…
Phase 1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control Recruiting nowThis study tests a new treatment for adults with advanced head and neck cancer that has spread or come back. The treatment uses donor immune cells that are engineered to target two cancer markers, EGFR and HER2. Participants first receive chemotherapy to prepare their body, then …
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New biologic JLM019 enters human testing for advanced cancers
Disease control Recruiting nowThis early-phase study is testing a new biologic drug called JLM019 in adults with advanced solid tumors or lymphomas that have come back or not responded to treatment. The drug is given as a weekly intravenous infusion, and the main goals are to check its safety, find the right …
Phase 1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Chilling out to fight cancer: cold therapy meets immunotherapy in new trial
Disease control Recruiting nowThis early-phase study tests whether spending time in a cool room (around 18°C for 12 hours a day) can make standard immunotherapy drugs work better for people with solid tumors. Twenty-four adults with various solid cancers will receive cold exposure alongside their usual PD-1/P…
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New hope for rare cancer: targeted drug afatinib tested in fanconi anemia patients
Disease control Recruiting nowThis study tests a drug called afatinib in 25 adults with Fanconi anemia who have advanced head and neck cancer that cannot be removed by surgery. Afatinib is a pill that blocks a protein helping cancer grow. The goal is to see if it can shrink tumors and control the disease. Res…
Phase 1/2 • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Could less radiation be just as effective for HPV+ throat cancer?
Disease control Recruiting nowThis study is testing whether a lower dose of radiation (30 Gy) can safely treat HPV-positive oropharyngeal cancer while reducing side effects. About 31 adults with this type of throat cancer will receive the reduced radiation along with standard chemotherapy. The main goal is to…
Phase 2 • Sponsor: Sara Medek • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New hope for kids with tough cancers: targeted drug trial launches
Disease control Recruiting nowThis study tests a new drug called Becotatug Vedotin in children aged 2 to 18 with certain solid tumors that have come back or spread. The drug targets a protein called EGFR found on many cancer cells. The main goal is to see if the drug is safe and to find the best dose, while a…
Phase 1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Could a common numbing drug help fight throat cancer?
Disease control Recruiting nowThis early-stage trial is testing whether injecting the local anesthetic lidocaine into HPV-related throat tumors before robotic surgery is safe and might help destroy more cancer cells. About 30 adults with HPV-positive oropharyngeal cancer will receive the injection during a ro…
Phase 1 • Sponsor: Ryan Carey • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Could a 3-Week radiation course replace 6 weeks for head and neck cancer?
Disease control Recruiting nowThis study compares a standard 6-week radiation course after surgery to a shorter 3-week course for people with head and neck cancer. The goal is to see if the shorter schedule works just as well at preventing cancer from coming back. About 369 participants will be randomly assig…
Phase 2/3 • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug duo takes on hard-to-treat head and neck cancer
Disease control Recruiting nowThis early-stage study tests two drugs (finotonlimab and stapokibart) together in 10 adults with head and neck cancer that has come back or spread. All participants have already tried standard treatments. The main goals are to see if the combination is safe and whether it shrinks…
Phase 1 • Sponsor: Beijing Tongren Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Oral cancer patients may avoid unnecessary radiation to the neck
Disease control Recruiting nowThis study tests whether it is safe to skip radiation to the lymph nodes in the neck after surgery for early-stage oral cancer. About 396 adults aged 18-70 with certain high-risk features will be randomly assigned to receive or not receive this radiation. The goal is to see if sk…
Phase 2/3 • Sponsor: All India Institute of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for head and neck cancer: smart drug targets tumors, boosts immune system
Disease control Recruiting nowThis phase 2 trial tests a new drug, GSK5764227, that delivers chemotherapy directly to cancer cells, either alone or with an immunotherapy called dostarlimab. The study enrolls 30 people with recurrent or metastatic head and neck cancer. Researchers will analyze tumor samples an…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New radiation 'Lattice' method paired with immunotherapy shows promise for tough cancers
Disease control Recruiting nowThis phase 2 trial tests a new radiation technique called lattice radiation therapy (LRT) combined with immunotherapy in 30 people with advanced solid tumors that have not responded to standard treatments. LRT delivers high doses of radiation to small spots inside the tumor while…
Phase 2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New dissolving plate could stop brain fluid leaks after nose surgery
Disease control Recruiting nowThis study tests a special plate that dissolves over time, placed during nose surgery to remove pituitary tumors. The plate supports the skull base to prevent spinal fluid leaks, a common complication. About 126 people aged 1 to 80 with sellar tumors will be randomly assigned to …
Phase 2 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Could less radiation be enough for HPV throat cancer? new trial aims to find out.
Disease control Recruiting nowThis study is testing whether people with early-stage HPV-positive throat cancer can be treated with radiation alone at a lower dose, instead of the usual full-dose radiation plus chemotherapy. The goal is to see if this gentler approach can keep the cancer from coming back while…
Sponsor: Georgetown University • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug ATG-022 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called ATG-022 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find a safe dose and check for side effects. Up to 156 participants will receive the drug every three…
Phase 1 • Sponsor: Antengene Biologics Limited • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New CAR-T therapy aims to outsmart Hard-to-Treat solid cancers
Disease control Recruiting nowThis early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Proton beam offers new hope for recurrent tumors
Disease control Recruiting nowThis study looks at whether proton therapy can safely treat cancers that return after standard radiation. Proton beams are more targeted than traditional X-rays, so they may deliver stronger doses to the tumor while sparing healthy tissue. Researchers will track side effects and …
Sponsor: The New York Proton Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Could immunotherapy spare throat cancer patients from losing their voice?
Disease control Recruiting nowThis phase 2 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy can help people with advanced laryngeal or hypopharyngeal cancer avoid having their voice box removed. The study will enroll 87 adults whose cancer has not been treated before…
Phase 2 • Sponsor: Matthew Spector • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New drug cocktail aims to extend life in Tough-to-Treat head and neck cancer
Disease control Recruiting nowThis Phase 3 trial is testing whether adding ficlatuzumab to the standard drug cetuximab helps people with recurrent or metastatic HPV-negative head and neck cancer live longer. About 410 adults will be randomly assigned to receive either the combination or a placebo plus cetuxim…
Phase 3 • Sponsor: AVEO Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment using donor immune cells (CAR-NK cells) that are engineered to recognize and attack cancer. The treatment is personalized based on a tumor's unique markers. It is for adults with advanced solid tumors that have not responded to other therapies. Th…
Phase 1/2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Off-the-Shelf immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing NK042, a ready-made natural killer cell therapy made from healthy donors, in 76 people with advanced solid tumors that have not responded to standard treatments. Participants first receive chemotherapy to prepare their immune system, then an infu…
Phase 1 • Sponsor: Shanghai NK Cell Technology Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Experimental virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …
Phase 1 • Sponsor: KaliVir Immunotherapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug combo shows promise for rare salivary gland cancer
Disease control Recruiting nowThis study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or stop them from growing. About 90 adults will take part, and the study is not…
Phase 2 • Sponsor: Ji Dongmei • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New daily pill hopes to control advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…
Phase 1/2 • Sponsor: 858 Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Heavy ion beam offers new hope for tough Head-and-Neck cancers
Disease control Recruiting nowThis study tests a precise type of radiation called carbon ion re-radiotherapy for people whose head-and-neck cancer has returned or worsened after standard treatment. About 72 adults who cannot have surgery will receive this therapy to see if it causes fewer severe side effects …
Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Gut health boost may tame immunotherapy side effects in head and neck cancer
Disease control Recruiting nowThis study tests whether a postbiotic supplement (Postbiotix-HLA™) can reduce immune-related side effects in 45 people with recurrent or metastatic head and neck cancer who are receiving the immunotherapy drug pembrolizumab. Participants will take either the supplement or a place…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New drug combo takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called INV-1120, either by itself or combined with the immunotherapy pembrolizumab (Keytruda), in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses an…
Phase 1 • Sponsor: Shenzhen Ionova Life Sciences Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could less radiation be better for head and neck cancer patients?
Disease control Recruiting nowThis study tests whether giving less radiation after surgery for certain head and neck cancers can reduce long-term side effects, like trouble swallowing, without allowing the cancer to come back. About 508 adults who have had surgery and need standard post-op radiation will be r…
Phase 2/3 • Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Common diabetes drug may shield kidneys from chemo damage
Disease control Recruiting nowThis study tests whether dapagliflozin, a drug used for diabetes, can prevent kidney damage caused by platinum-based chemotherapy in people with solid tumors. About 46 participants will receive either dapagliflozin or a placebo for a few days around their chemo session. Researche…
Phase 2 • Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Could a short, High-Dose drug course cure small pituitary tumors?
Disease control Recruiting nowThis study tests whether a higher dose of the drug cabergoline, taken for about 6 months, can achieve lasting remission in women with small prolactinomas (non-cancerous pituitary tumors that cause excess prolactin). 70 premenopausal women will be randomly assigned to either the h…
Phase 3 • Sponsor: University of Sao Paulo General Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New injection targets Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called tolododekin alfa (ANK-101) for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into the tumor to see if it is safe and tolerable. About 97 adults with various solid canc…
Phase 1 • Sponsor: Ankyra Therapeutics, Inc • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
One-shot radiation blast aims to zap liver tumors better
Disease control Recruiting nowThis study tests whether a single, extremely high dose of radiation, guided by advanced MRI technology, can control liver tumors that have spread from other cancers better than the usual high dose. About 114 adults with up to 3 liver metastases will be randomly assigned to receiv…
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug cocktail aims to shrink head and neck tumors before surgery
Disease control Recruiting nowThis phase 2 trial is testing whether giving two drugs—pembrolizumab (Keytruda) and IO102-103—before surgery is safe and effective for people with head and neck cancer. The study will enroll 30 adults whose cancer can be surgically removed. Researchers will watch for side effects…
Phase 2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Less radiation, same control? new trial aims to boost quality of life for throat cancer patients
Disease control Recruiting nowThis study tests whether a shorter, lower-dose course of radiation after robotic surgery can improve quality of life for people with HPV-related throat cancer. About 42 adults who have had robotic surgery will receive a reduced radiation schedule. The goal is to see if this appro…
Phase 2 • Sponsor: University of Utah • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug aims to wipe out lingering cancer DNA after standard treatment
Disease control Recruiting nowThis phase 2 study tests a drug called AZD2936 in people with high-risk head and neck cancer who still have traces of cancer DNA in their blood after completing standard treatment. The drug is designed to boost the immune system to find and destroy these remaining cancer cells. A…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Engineered donor cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…
Phase 1/2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Could early radiation prevent spine fractures in cancer patients?
Disease control Recruiting nowThis study tests whether giving radiation early to spine tumors that are not yet painful can prevent serious problems like fractures or spinal cord compression. About 74 adults with cancer that has spread to the spine will receive radiation before symptoms get worse. The goal is …
Phase 1/2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New shorter radiation therapy could tame brain tumors
Disease control Recruiting nowThis study tests a shorter course of high-dose proton radiation for people with non-cancerous brain tumors like meningiomas and schwannomas. The goal is to see if fewer treatments can still control tumor growth while reducing side effects and being more convenient. About 70 adult…
Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Immune cell therapy takes on Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…
Phase 1/2 • Sponsor: Essen Biotech • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New study seeks safer dosing of cancer drug for patients with liver issues
Disease control Recruiting nowThis early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receiv…
Phase 1 • Sponsor: Acrotech Biopharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Radiation after surgery may keep tongue cancer at bay for High-Risk patients
Disease control Recruiting nowThis study looks at whether giving radiation therapy after surgery can delay the return of early-stage tongue cancer in patients who have certain risk factors. About 190 adults aged 18 to 70 will be randomly assigned to either receive radiation or just be monitored. The goal is t…
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New scan could reveal how well your immune system fights cancer
Diagnosis Recruiting nowThis study tests an experimental imaging agent (89Zr-DFO-REGN5054) that may help visualize immune cells called CD8+ T cells in tumors. About 50 people with advanced solid cancers will receive the imaging agent along with the immunotherapy drug cemiplimab. The main goal is to chec…
Phase 1 • Sponsor: Regeneron Pharmaceuticals • Aim: Diagnosis
Last updated Sep 21, 2026 21:00 UTC
-
Can a blood test model flag dangerous myelosuppression before it strikes?
Diagnosis Recruiting nowResearchers are evaluating a dynamic risk prediction model for severe myelosuppression in adults with nasopharyngeal carcinoma who receive systemic anticancer treatment. The model estimates the risk of grade 3 or higher anemia, low platelets, or low white blood cells during thera…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Diagnosis
Last updated Sep 17, 2026 00:00 UTC
-
Glowing dye lights up throat tumors during surgery
Diagnosis Recruiting nowResearchers are testing whether a fluorescent dye called cRGD-ZW800-1 can help surgeons see laryngeal and hypopharyngeal tumors more clearly during total laryngectomy. The trial has two parts: first, to find the best dose of the dye by measuring how brightly it lights up tumor ti…
Phase 2 • Sponsor: Erasmus Medical Center • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Blood test aims to catch Cancer's return earlier
Diagnosis Recruiting nowThe ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…
Sponsor: Guardant Health, Inc. • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
Glowing dye could light up leftover cancer cells at surgery edges
Diagnosis Recruiting nowResearchers at Erasmus Medical Center are testing whether a fluorescent imaging agent can highlight cancer cells on the surface of tumor tissue removed during surgery. The study involves 200 adults with solid tumors who are scheduled for surgery. After the tumor is removed, the d…
Sponsor: Erasmus Medical Center • Aim: Diagnosis
Last updated Sep 13, 2026 00:00 UTC
-
Million-Person quest to catch a silent cancer early
Diagnosis Recruiting nowThis study aims to build a massive screening cohort of one million people to improve early detection of nasopharyngeal carcinoma, a cancer linked to Epstein-Barr virus (EBV). Participants aged 30 to 69 will provide blood, saliva, and nasal brush samples for EBV antibody and DNA t…
Sponsor: Ming-Yuan Chen • Aim: Diagnosis
Last updated Sep 03, 2026 00:00 UTC
-
MRI 'Fingerprint' may reveal which head and neck tumors vanish with Pre-Surgery therapy
Diagnosis Recruiting nowThis study tests whether a computer model that analyzes MRI images can predict which patients with head and neck cancer will have a complete response to neoadjuvant therapy, which combines chemotherapy and immunotherapy before surgery. Researchers will build the model using MRI s…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a simple blood test catch Cushing's earlier?
Diagnosis Recruiting nowThis study aims to improve how doctors diagnose Cushing's syndrome, a condition caused by too much cortisol. Researchers will test the accuracy of the desmopressin stimulation test in 140 people aged 18-70 who have or may have Cushing's, plus healthy volunteers. Participants will…
Phase 2 • Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a glowing mouthwash spot oral cancer before biopsy?
Diagnosis Recruiting nowThis trial tests a fluorescent probe called TTP-ICG that targets Trop2, a protein often found on oral cancer cells. Researchers will soak tissue samples from people with oral tumors in the probe and use near-infrared imaging to see if it can distinguish cancer from benign growths…
Sponsor: Yunnan Cancer Hospital • Aim: Diagnosis
Last updated Sep 02, 2026 00:00 UTC
-
Can a scan tell who needs more surgery after head and neck cancer?
Diagnosis Recruiting nowThis study looks at whether PET/CT scans can accurately detect remaining cancer in lymph nodes after a person has completed curative radiation for head and neck cancer. About 600 adults who finished treatment will receive a PET/CT scan, and those with suspicious findings may unde…
Sponsor: Rigshospitalet, Denmark • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Can a simple swab predict who needs less radiation?
Diagnosis Recruiting nowThis trial is testing a new electrochemical method to monitor HPV infection in patients with head and neck cancers, specifically oropharyngeal carcinoma. The goal is to see if tracking HPV DNA levels during treatment can help personalize therapy, potentially allowing some patient…
Sponsor: Masaryk Memorial Cancer Institute • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New PET scan could end guesswork after head and neck cancer radiation
Diagnosis Recruiting nowThis study is testing a new type of PET scan to see if it can tell the difference between cancer that is still there and swelling caused by radiation treatment in people with head and neck cancer. About 180 adults who finished radiation therapy will get this special scan 3 months…
Sponsor: University Hospital, Brest • Aim: Diagnosis
Last updated Jul 15, 2026 00:00 UTC
-
Phone AI could spot eye disease in remote areas
Diagnosis Recruiting nowThis study tests a smartphone app that uses artificial intelligence to detect 16 different eye diseases from photos taken with the phone. The AI works entirely on the device, so no internet is needed. Researchers will compare its accuracy to eye doctors and see if non-medical use…
Sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University • Aim: Diagnosis
Last updated Jun 27, 2026 13:05 UTC
-
Spit test could spot oral cancer before it spreads
Diagnosis Recruiting nowThis study is testing whether a simple saliva sample can help diagnose oral squamous cell carcinoma (OSCC), a type of mouth cancer. Researchers will look for specific DNA changes (methylation) in the saliva of 30 patients with OSCC and compare them to 30 healthy controls. If the …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Diagnosis
Last updated Jun 27, 2026 12:32 UTC
-
New scan spots hidden cancer spread before surgery
Diagnosis Recruiting nowThis Phase 2 trial tests whether a special PET/CT scan using [68Ga]Ga-FAPI-46 can detect early lymph node metastases in people with head and neck squamous cell carcinoma. The scan targets cancer-associated fibroblasts, which help create a welcoming environment for cancer to sprea…
Phase 2 • Sponsor: John O. Prior • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
New PET scan could spot tiny brain tumors missed by MRI
Diagnosis Recruiting nowThis study is testing whether a special PET scan using [18F]FET can better locate small pituitary tumors that cause Cushing's disease. Standard MRI misses these tumors in up to 30% of cases. Researchers will compare PET results with MRI and surgical findings in 20 adults to see i…
Sponsor: Hospices Civils de Lyon • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New ultrasound wand could spot mouth cancer without a knife
Diagnosis Recruiting nowThis study is testing a new, high-frequency ultrasound probe that goes inside the mouth to look at suspicious spots. The goal is to see if it can accurately measure how deep a mouth cancer goes, which might help doctors diagnose it without always needing a surgical biopsy. The st…
Sponsor: University of Pisa • Aim: Diagnosis
Last updated Jun 27, 2026 09:08 UTC
-
New shot could stop deadly clots in cancer patients
Prevention Recruiting nowThis phase 3 trial tests an experimental drug called REGN7508 to prevent blood clots in people with solid tumors who are receiving cancer treatment. About 1,120 participants will receive either the drug or a placebo. The study measures how well the drug prevents clots and checks …
Phase 3 • Sponsor: Regeneron Pharmaceuticals • Aim: Prevention
Last updated Sep 17, 2026 00:00 UTC
-
Could a probiotic cream shield cancer patients from radiation burns?
Prevention Recruiting nowThis early-stage trial tests a cream made from inactivated Akkermansia muciniphila bacteria to prevent skin injury in 40 breast or head/neck cancer patients receiving radiation. The cream is applied three times daily to the radiation area. The main goal is to see if it is safe an…
Phase 1 • Sponsor: West China Hospital • Aim: Prevention
Last updated Sep 11, 2026 00:00 UTC
-
Can a new drug shield nerves from Chemotherapy's side effects?
Prevention Recruiting nowThis phase 2 trial is testing an experimental drug called SIR2501 in adults with solid tumors who are about to receive paclitaxel-based chemotherapy. The goal is to see if SIR2501 is safe, tolerable, and might reduce the development of chemotherapy-induced peripheral neuropathy—a…
Phase 2 • Sponsor: Sironax USA, Inc. • Aim: Prevention
Last updated Sep 03, 2026 00:00 UTC
-
Could a virus injection stop oral cancer before it starts?
Prevention Recruiting nowThis study is testing a new immune therapy called RP2, made from a modified herpes virus, to treat high-risk oral precancerous conditions and prevent them from turning into oral cancer. The therapy is injected directly into the lesion. The trial will enroll 25 people and look at …
Phase 2 • Sponsor: Glenn J. Hanna • Aim: Prevention
Last updated Jun 27, 2026 12:23 UTC
-
Zinc spray may stop painful mouth sores in cancer radiation
Prevention Recruiting nowThis study tests whether a zinc-based spray (Gel X) can prevent painful mouth sores caused by radiation therapy for head and neck cancer. About 130 adults receiving radiation will use either the zinc spray or a sodium bicarbonate rinse. The goal is to see if the spray reduces how…
Sponsor: Catholic University of the Sacred Heart • Aim: Prevention
Last updated Jun 27, 2026 11:03 UTC
-
FLASH therapy: a flash of hope for head and neck cancer retreatment?
Symptom relief Recruiting nowThis early study tests a new type of radiation therapy called ConformalFLASH, which delivers radiation at an ultra-high speed. It is for 10 adults with head and neck cancer who need a second round of radiation but cannot have surgery. The goal is to see if this fast treatment is …
Sponsor: IBA Proton Therapy, Inc. • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Light therapy app aims to ease dry mouth for cancer survivors
Symptom relief Recruiting nowThis study tests whether a special light therapy (photobiomodulation) combined with a mobile health app can improve dry mouth and quality of life in people who have had head and neck cancer and completed radiation. Sixty participants will receive either real light therapy or a sh…
Sponsor: Universidad de Granada • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New 'Lattice' radiation aims to zap tumor pain better than standard therapy
Symptom relief Recruiting nowThis phase 3 trial compares lattice radiation therapy (LRT) to standard radiation for reducing pain from large solid tumors (at least 5 cm). About 148 adults whose tumors cannot be surgically removed will be randomly assigned to one of the two radiation approaches. The main goal …
Phase 3 • Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Can tai chi ease the exhaustion of cancer radiotherapy?
Symptom relief Recruiting nowResearchers are testing whether a 12-week Tai Chi program can reduce cancer-related fatigue in people with head and neck cancer who are receiving radiotherapy. The trial enrolls 116 adults who do not exercise regularly. Half join a supervised Yang-style 16-form Tai Chi group alon…
Sponsor: West China Hospital • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
New hope for cancer patients suffering from severe diarrhea and colitis from immunotherapy
Symptom relief Recruiting nowThis study tests if the drug ustekinumab can control diarrhea and colon inflammation caused by immune checkpoint inhibitors in cancer patients. Ten adults with solid tumors who have moderate to severe symptoms will receive ustekinumab and be monitored for side effects and symptom…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
New radiation method aims to save swallowing in cancer patients
Symptom relief Recruiting nowThis study tests a new way to give radiation to people with head and neck cancer. The goal is to see if protecting the parts of the throat used for swallowing can help patients eat and drink better after treatment. About 136 adults with certain types of head and neck cancer will …
Phase 3 • Sponsor: All India Institute of Medical Sciences • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a 2-Week Pre-Surgery program help head and neck cancer patients?
Symptom relief Recruiting nowThis study tests whether a 2-week exercise and nutrition program is safe and doable for people about to have head and neck cancer surgery. About 20 adults with a new diagnosis will take part. The goal is to see if the program helps patients feel stronger before their operation.
Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Magic mushroom therapy targets Cancer-Related depression
Symptom relief Recruiting nowThis phase 2 trial at MD Anderson Cancer Center is testing whether psilocybin-assisted psychotherapy can safely help ease depression and anxiety in 30 adults with advanced cancer who are on maintenance therapy. Participants receive either psilocybin or a placebo (niacin) along wi…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a Nerve-Blocking injection prevent salivary complications after parotid surgery?
Symptom relief Recruiting nowAfter surgery to remove a benign parotid tumor, some people develop salivary fistulas or sialoceles, which are collections of saliva that can leak or cause swelling. This pilot study tests whether injecting a long-acting local anesthetic called bupivacaine, combined with a steroi…
Early phase 1 • Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
New lozenge aims to ease radiation mouth sores for hours
Symptom relief Recruiting nowThis phase 3 trial tests whether a lozenge called BupiZenge, which contains the long-acting painkiller bupivacaine, can relieve mouth pain from radiation therapy better than the standard lidocaine rinse. About 150 adults with head and neck cancer will be randomly assigned to one …
Phase 3 • Sponsor: OncoZenge AB • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can an antidepressant calm Chemotherapy's nerve pain?
Symptom relief Recruiting nowThis trial tests whether duloxetine, a drug commonly used for depression, can reduce the painful nerve damage that some cancer patients experience after receiving taxane chemotherapy. The study enrolls adults with solid tumors who have at least moderate pain from this side effect…
Phase 2 • Sponsor: Yan Yang, MD, Ph.D • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New therapy aims to ease spiritual distress in latino cancer patients
Symptom relief Recruiting nowThis study adapts a counseling program called Meaning Centered Psychotherapy for Latinos with advanced cancer. The goal is to improve spiritual well-being and quality of life. Researchers will enroll 190 Latino adults with stage III or IV solid tumors to test the program's feasib…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Can a 6-Week video therapy ease body image pain for head and neck cancer survivors?
Symptom relief Recruiting nowThis study tests a brief video-based cognitive behavioral therapy (BRIGHT) to reduce body image distress in 180 head and neck cancer survivors. Participants are randomly assigned to either BRIGHT or a supportive care control group. The goal is to see if BRIGHT can help survivors …
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Can a Self-Care program ease Post-Cancer swelling in the head and neck?
Symptom relief Recruiting nowThis study tests whether a structured self-management program can help head and neck cancer survivors cope with lymphedema and fibrosis, which cause swelling and stiffness after treatment. Participants will either follow their usual care or learn the program in person or through …
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Cholesterol drug shows promise for cancer Survivors' swallowing woes
Symptom relief Recruiting nowThis study tests whether a common cholesterol medication, pravastatin, can improve swallowing difficulties caused by past radiation treatment for head and neck cancer. Researchers will give 48 participants pravastatin daily for 12 months and monitor changes in swallowing function…
Phase 2 • Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Digital peer support: a new weapon against cancer treatment anxiety?
Symptom relief Recruiting nowThis trial tests whether a mobile app that encourages social sharing and peer interaction can reduce anxiety and depression in people with head and neck cancer undergoing radiotherapy. Half of the 120 participants will use the app for eight weeks, while the other half receives a …
Sponsor: West China Hospital • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Cholesterol drug may shield ears from chemo damage
Symptom relief Recruiting nowThis study tests whether atorvastatin, a widely used cholesterol medication, can reduce hearing loss caused by cisplatin chemotherapy in people with head and neck cancer. About 224 adults will be randomly assigned to take atorvastatin or a placebo daily during and for three month…
Phase 2 • Sponsor: National Institute on Deafness and Other Communication Disorders (NIDCD) • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Can pre-treatment nutrition and exercise ease head and neck cancer therapy?
Symptom relief Recruiting nowThis study looks at whether offering nutritional counseling and exercise programs before and during radiation or chemoradiation is helpful for head and neck cancer patients. Researchers want to see if patients are willing to join and attend these sessions. The goal is to improve …
Sponsor: University of Miami • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
A pill to stop cancer treatment from stealing appetite?
Symptom relief Recruiting nowThis phase 3 trial tests whether megestrol acetate, a drug that stimulates appetite, can prevent weight loss in people with nasopharyngeal carcinoma undergoing chemoradiotherapy. Half of the 204 participants will take the drug daily for 11 weeks, and the other half will take a pl…
Phase 3 • Sponsor: Sun Yat-sen University • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
New breathing method may make throat scopes safer and easier
Symptom relief Recruiting nowThis study tests if a high-flow oxygen device can replace the usual oxygen tube placed through the nose during throat and voice box exams. About 610 adults having this procedure will be randomly assigned to either the standard method or the new one. The goal is to see if the new …
Sponsor: Poitiers University Hospital • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Glow-in-the-Dark dye could save voices in thyroid surgery
Symptom relief Recruiting nowThis phase 2 trial tests a dye called bevonescein that makes nerves glow during thyroid surgery, helping surgeons see and avoid them. Forty adults having thyroid removal will receive the dye before surgery. The main goal is to see if it improves voice outcomes by reducing nerve i…
Phase 2 • Sponsor: Matthew Spector • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Cactus extract could zap cancer pain in new trial
Symptom relief Recruiting nowThis early-stage study tests a drug called resiniferatoxin (RTX), a chemical from a cactus-like plant similar to hot pepper, for people with severe cancer pain that standard treatments can't control. RTX is injected into the spine to destroy pain-transmitting nerves. The trial in…
Phase 1 • Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Symptom relief
Last updated Sep 02, 2026 00:00 UTC
-
Heat therapy as a palliative aid: does raising body temperature ease advanced cancer symptoms?
Symptom relief Recruiting nowThis study looks at whether a noninvasive treatment called whole-body infrared hyperthermia can help people with advanced solid tumors feel better. The therapy uses infrared energy to raise body temperature in a controlled way, and researchers will track changes in pain, fatigue,…
Sponsor: Zhejiang Hospital • Aim: Symptom relief
Last updated Aug 30, 2026 00:00 UTC
-
Can ditching the mask make radiation therapy more comfortable?
Symptom relief Recruiting nowThis trial is testing whether head and neck cancer patients can undergo radiation therapy without a restrictive face mask, using a surface-guided system that tracks their position with infrared light. Half of the participants will receive treatment with a standard closed face mas…
Sponsor: University of Zurich • Aim: Symptom relief
Last updated Aug 22, 2026 00:00 UTC
-
Tongue training device aims to restore speech after cancer surgery
Symptom relief Recruiting nowThis study tests whether starting tongue strengthening exercises early, using a device called the Tongueometer, can improve speech and swallowing in people who have had part of their tongue removed due to cancer. The device uses a small air-filled bulb and a mobile app to guide e…
Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Can a short talk with biofeedback ease trauma after cancer surgery?
Symptom relief Recruiting nowThis study tests whether two 60-minute psychological sessions that include biofeedback can help reduce post-traumatic stress symptoms in people undergoing surgery for head and neck cancer. Participants are randomly assigned to receive the intervention or standard care. The goal i…
Sponsor: University of Turin, Italy • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Early phase 1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could a nurse-led online therapy beat severe fatigue in advanced cancer?
Symptom relief Recruiting nowThis trial investigates whether an online, nurse-guided version of cognitive behavioral therapy (CBT) can reduce severe fatigue in people with advanced cancer who are receiving palliative systemic treatment. Participants complete a 12-week online CBT program with support from the…
Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Can sexology consultations restore intimacy after throat cancer surgery?
Symptom relief Recruiting nowThis study tests whether a series of sexology consultations can help people who had their voice box removed due to throat cancer, along with their partners, feel better about their intimate lives. The program involves individual talks with a trained sexology nurse and questionnai…
Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New tool aims to ease the journey for head and neck cancer survivors and caregivers
Symptom relief Recruiting nowThis study tests a program called SNAP that helps head and neck cancer survivors and their caregivers after radiation treatment. The program includes a needs assessment, a personalized care plan, and a mobile app. Researchers want to see if it reduces symptoms for survivors and e…
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Jun 27, 2026 13:07 UTC
-
No drain, Same-Day discharge? new study tests safer parotid surgery
Symptom relief Recruiting nowThis study is testing whether it is safe to remove a tumor from the parotid gland (a saliva gland near the ear) without using a surgical drain. Normally, a drain is placed to remove extra fluid, which often requires an overnight hospital stay. The researchers want to see if skipp…
Sponsor: Uppsala University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:03 UTC
-
Can early speech therapy help cancer patients swallow and speak better after surgery?
Symptom relief Recruiting nowThis study looks at whether starting speech and swallowing therapy early — before and just after surgery — can help people with head and neck cancer recover better. Forty patients will either get early therapy sessions with a speech-language pathologist or the usual care. The mai…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Can a skin cell spray help scars blend in? new study aims to find out
Symptom relief Recruiting nowThis study tests whether using RECELL® — a device that creates a spray from a patient's own skin cells — can improve skin color matching after head and neck reconstructive surgery. Twenty adults who need this surgery will receive the treatment, and their color match, healing, and…
Sponsor: Yale University • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
New radiation approach aims to cut painful side effects in head and neck cancer
Symptom relief Recruiting nowThis study tests if proton radiation causes fewer side effects than standard photon radiation in people with head and neck cancer. About 400 adults aged 40 and older will receive either proton or photon therapy, plus possible chemotherapy. The main goal is to see if protons reduc…
Phase 3 • Sponsor: Oslo University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Can dietitian Check-Ins prevent weight loss after head and neck cancer surgery?
Symptom relief Recruiting nowThis study tests whether extra nutritional counseling helps head and neck cancer patients maintain their weight after surgery. 60 adults having surgery for head and neck cancer will be split into two groups: one gets standard care, the other gets extra support from a dietitian an…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Robotic surgery plus daily swallowing therapy aims to keep head and neck cancer patients eating and speaking normally
Symptom relief Recruiting nowThis study tests whether a personalized 12-week speech, swallowing, and voice rehabilitation program can help preserve swallowing function in head and neck cancer patients after minimally invasive robotic surgery. About 53 participants will be enrolled, including those having sur…
Sponsor: Christian Simon • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Can a simple mouth device restore speech after tongue cancer?
Symptom relief Recruiting nowThis study tests whether a custom dental device called a palatal augmentation prosthesis (PAP), along with speech therapy, can improve how well people speak and swallow after surgery for small tongue cancers (T1/T2). Forty participants will be randomly assigned to receive the dev…
Sponsor: University of Michigan • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
Card game aims to ease tough End-of-Life talks for cancer patients
Symptom relief Recruiting nowThis study tests whether a simple card game, the Go Wish Game, can help people with advanced blood cancers or solid tumors discuss their end-of-life priorities with doctors. About 75 patients will use the cards to sort what matters most to them, then complete an advance care plan…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Symptom relief
Last updated Jun 27, 2026 12:30 UTC
-
New day hospital aims to ease transition for young cancer survivors
Symptom relief Recruiting nowThis study looks at whether a one-day hospital visit that includes medical, psychological, and social support can help teens and young adults (ages 15-25) feel better after finishing cancer treatment. About 214 participants who have completed treatment for a solid tumor or lympho…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Spa treatment may ease radiation skin damage in cancer survivors
Symptom relief Recruiting nowThis study tests whether a special spa therapy can improve skin-related quality of life in people who have skin hardening (fibrosis) after radiation for breast or head/neck cancer. About 110 adults who finished radiation at least 6 months ago will be randomly assigned to receive …
Sponsor: Association Francaise pour la Recherche Thermale • Aim: Symptom relief
Last updated Jun 27, 2026 12:06 UTC
-
Jelly supplement aims to ease chemo side effects in cancer patients
Symptom relief Recruiting nowThis study is testing a jelly-based nutritional supplement in 52 people with head and neck, lung, or rectal cancer who are receiving standard cancer treatments like chemo or radiation. The supplement contains ingredients like arginine, omega-3, and olive oil, and is taken twice d…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Extra care days after cancer surgery may ease anxiety
Symptom relief Recruiting nowThis study looks at whether adding three extra support visits after surgery can lower anxiety and improve quality of life for people with head and neck cancers. About 60 patients will take part. The goal is to see if more follow-up care helps patients cope better after their oper…
Sponsor: Clinique Pasteur Lanroze • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Smart radiotherapy aims to cut cancer treatment side effects
Symptom relief Recruiting nowThis study tests a new way to give radiation for head and neck cancer. Instead of a fixed plan, the radiation is adjusted daily to match changes in the patient's body. The goal is to lower side effects like trouble swallowing and dry mouth. About 40 adults with throat or voice-bo…
Sponsor: Rigshospitalet, Denmark • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Light therapy tested to reverse radiation damage in head and neck cancer patients
Symptom relief Recruiting nowThis study tests whether a special light therapy called photobiomodulation (PBM) can reduce swelling and tissue hardening caused by radiation treatment in head and neck cancer survivors. Sixty participants who completed radiation at least 3 months ago will be randomly assigned to…
Sponsor: NYU Langone Health • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Could ozone gas soothe cancer Patients' painful mouth sores?
Symptom relief Recruiting nowThis study tests whether applying medical ozone gas to mouth sores can reduce pain and severity in people undergoing radiation or chemotherapy for head and neck cancer. Fifty participants will receive ozone therapy, and half will also use a special toothpaste and mouthwash at hom…
Sponsor: University of Pavia • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Exercise program aims to get head and neck cancer patients off the couch
Symptom relief Recruiting nowThis study tests whether a structured physical activity program can reduce how much time head and neck cancer patients spend sitting or lying down. Researchers will track 96 patients over 18 months, measuring their movement, quality of life, and fatigue. Half the patients will fo…
Sponsor: Centre Hospitalier de Valence • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Nurse chats could ease cancer kids' suffering
Symptom relief Recruiting nowThis study tests whether specially trained nurses can help children with cancer and their families by starting conversations about palliative care early. About 120 children recently diagnosed with cancer will be randomly assigned to either receive these nurse-led talks or standar…
Sponsor: Children's Hospital of Fudan University • Aim: Symptom relief
Last updated Jun 27, 2026 11:02 UTC
-
Prehab before cancer surgery may boost recovery
Symptom relief Recruiting nowThis study tests whether a program of targeted exercise and psychological support before cancer treatment (called prehabilitation) can help patients with solid tumors recover better physically and emotionally. Researchers will compare this program to standard care in 125 adults w…
Sponsor: Priv.-Doz. Dr. med. Philipp Lenz • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Could a simple injection cut pain after brain surgery?
Symptom relief Recruiting nowThis study tests whether injecting a numbing medication (bupivacaine) near a nerve cluster in the nose can reduce pain after minimally invasive pituitary tumor removal. About 108 adults will be randomly assigned to receive the nerve block, a placebo (saline), or no extra injectio…
Phase 4 • Sponsor: Hamilton Health Sciences Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Chatbot coaches cancer patients through radiotherapy stress
Symptom relief Recruiting nowThis study tests a chatbot called Digi-Coach to see if it can reduce physical and emotional distress in people receiving radiotherapy for head and neck cancer. About 138 adults will either use the chatbot alongside standard nursing care or receive usual care alone. The goal is to…
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New trial uses DNA tests to match cancer patients to targeted drug cocktails
Knowledge-focused Recruiting nowThis large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 21, 2026 21:00 UTC
-
Can a tiny doppler turn blood flow sounds into pictures to save rebuilt tissue?
Knowledge-focused Recruiting nowResearchers at Mayo Clinic are studying whether an implantable Doppler monitor can record the sound of blood flowing through a free flap and convert it into a visual signal. The trial enrolls 100 adults scheduled for free flap surgery, a procedure that moves tissue to rebuild par…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Sep 21, 2026 21:00 UTC
-
New study checks cancer Drug's effect on common medications
Knowledge-focused Recruiting nowThis study looks at how a cancer drug called pelabresib changes the way the body processes three other medicines: repaglinide (for diabetes), midazolam (a sedative), and a birth control pill. It involves 24 adults with advanced cancers who have no standard treatment options. The …
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Gene therapy survivors monitored for years in massive safety study
Knowledge-focused Recruiting nowThis study follows over 1,500 children and adults who previously received gene-modified T cell therapy for cancer. Researchers will track side effects, how long the modified cells last, and overall survival for up to 15 years. No new treatment is given—the goal is to understand l…
Phase 2/3 • Sponsor: Celgene • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study checks how liver issues affect cancer drug pelabresib
Knowledge-focused Recruiting nowThis early-phase study is testing the cancer drug pelabresib in 24 people with advanced cancers who also have liver problems. The goal is to see how the liver affects the drug levels in the body. Participants will take the drug daily for 14 days, then have a week off. This resear…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists launch major study to unravel salivary gland mysteries
Knowledge-focused Recruiting nowThis study aims to learn more about diseases that affect the salivary glands, which produce saliva. Researchers will collect medical data, blood, saliva, and tissue samples from people with these conditions, their relatives, and healthy volunteers. The goal is to better understan…
Sponsor: National Institute of Dental and Craniofacial Research (NIDCR) • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Scientists watch thyroid conditions unfold in 2,500 patients
Knowledge-focused Recruiting nowThis study follows up to 2,500 people with thyroid problems like hyperthyroidism, hypothyroidism, or Graves' disease. Researchers will track how these conditions develop over time using standard medical tests and genetic samples. The goal is to better understand the natural histo…
Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Rare cancer syndrome under the microscope: what families need to know
Knowledge-focused Recruiting nowThis study follows people with a rare genetic condition called DICER1 syndrome, which raises the risk of certain childhood cancers like pleuropulmonary blastoma. Researchers will collect medical histories, genetic samples, and tissue from up to 1,500 participants and their relati…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can tailored nutrition boost recovery from head and neck surgery?
Knowledge-focused Recruiting nowThis study looks at how many calories patients with head and neck cancer need before and after free flap reconstructive surgery. Researchers will use indirect calorimetry to measure energy use at several time points, along with body composition and diet questionnaires. The goal i…
Sponsor: Tel-Aviv Sourasky Medical Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Cured of cushing as a kid? scientists want to track your health for years
Knowledge-focused Recruiting nowThis study looks at the long-term health of people who were cured of Cushing disease before age 21. Researchers want to understand how past high cortisol levels affect the body and mind years later. Participants will complete surveys and have check-ups every 5 years. The goal is …
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Morning or afternoon? new study tests if immunotherapy timing boosts cancer fight
Knowledge-focused Recruiting nowThis study looks at whether getting immunotherapy infusions in the morning versus the afternoon changes outcomes for people with advanced lung cancer or head and neck cancer. About 238 participants will be randomly assigned to morning or afternoon infusions. Researchers will trac…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New scanner could help surgeons see cancer in removed tissue instantly
Knowledge-focused Recruiting nowThis study is testing a new PET-CT scanner that takes high-resolution images of tissue removed during cancer surgery. Researchers want to see if these images match lab results and help surgeons make better decisions. The study will include 850 people with prostate, breast, head a…
Sponsor: XEOS Medical • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Stanford launches massive study to track oropharyngeal cancer over time
Knowledge-focused Recruiting nowThis study aims to learn more about oropharyngeal carcinoma, a type of throat cancer that can be linked to HPV. Researchers will collect blood samples from 1,000 patients before treatment and at six follow-up visits, and also gather tumor tissue when available. The goal is to bet…
Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can science predict cancer fatigue? new study seeks answers
Knowledge-focused Recruiting nowThis study tracks 125 cancer patients receiving standard chemotherapy and radiation to understand why they feel tired. Researchers will collect blood, stool, and survey data before, during, and after treatment. The goal is to find patterns that could help predict and manage fatig…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Blood test may outshine scans for spotting hidden cancer after radiation
Knowledge-focused Recruiting nowThis study is testing whether a simple blood test that looks for tumor DNA can better detect any cancer left behind after radiation therapy for advanced head and neck cancer. Current scans often give false alarms, leading to unnecessary procedures. The study will enroll 63 adults…
Sponsor: Centre Jean Perrin • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Blood test may spot hidden cancer after chemoradiation
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test can find leftover cancer cells in people treated for advanced head and neck cancer. About 59 participants will give blood samples one and three months after finishing chemoradiotherapy. Researchers will compare the blood test result…
Sponsor: Centre Jean Perrin • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
New study aims to unlock Radiation's hidden effects on head and neck cancer
Knowledge-focused Recruiting nowThis study is for people newly diagnosed with head and neck squamous cell carcinoma who are scheduled for curative surgery or radiation therapy. Researchers want to see how radiation changes MRI scans and immune-related markers in tumors. About 40 participants will be randomly as…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
What do you risk for a chance at remission? cell therapy survey asks
Knowledge-focused Recruiting nowCell therapies such as CAR-T and TIL therapy are emerging options for advanced solid tumors, but their benefits are uncertain and side effects can be severe. Researchers at Zhejiang University are surveying about 420 cancer doctors and 600 patients in China to learn how each grou…
Sponsor: Zhejiang University • Aim: Knowledge-focused
Last updated Sep 12, 2026 00:00 UTC
-
Study tests if simple info sheets can boost dental care for cancer patients
Knowledge-focused Recruiting nowThis study looks at whether giving written, guideline-based information to head and neck cancer patients and their dentists can improve their knowledge and decisions about dental care. About 132 participants will fill out surveys before and after reading the materials. The goal i…
Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
3D-Printed guides could make jaw surgery more precise
Knowledge-focused Recruiting nowThis study compares two ways to rebuild the jaw after oral cancer surgery: standard free-hand surgery versus using 3D-printed guides made from virtual planning. About 420 adults needing jaw reconstruction will be randomly assigned to one method. The main goal is to see which appr…
Sponsor: University of British Columbia • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Scientists hunt for genetic clues behind childhood pituitary tumors
Knowledge-focused Recruiting nowThis study aims to uncover the genetic causes of pituitary and hypothalamic tumors in children. Researchers will collect blood and tumor samples from up to 2,000 participants to analyze DNA and look for inherited patterns. The study also trains doctors and tests new MRI technique…
Sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study gathers key materials to create personalized cell therapies for tough cancers
Knowledge-focused Recruiting nowThis observational study collects tumor tissue and blood cells from 200 people with advanced solid tumors like colorectal, lung, and pancreatic cancers. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for potential fu…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
Blood biomarkers may predict cancer treatment side effects
Knowledge-focused Recruiting nowThis pilot study investigates whether certain molecules in the blood, called miRNAs and proteins, change during cancer treatment and whether these changes can signal early signs of heart or lung damage. Researchers will compare blood samples from patients receiving radiation or c…
Sponsor: University Hospitals Coventry and Warwickshire NHS Trust • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
500 cancer patients join quest to unlock hidden clues in their blood and tumors
Knowledge-focused Recruiting nowThis study enrolls 500 adults with advanced head and neck cancer who are starting standard immunotherapy. Researchers will collect blood and tumor samples over time to look for genetic and immune markers that may predict how well treatment works or why it stops working. The goal …
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
AI tool aims to spot head and neck cancer risk early
Knowledge-focused Recruiting nowThis study will use artificial intelligence to create a risk prediction model for head and neck cancers, including cancers of the throat and voice box. Researchers will collect data from 3000 participants, including their medical history, lifestyle habits, and laryngoscopy images…
Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
AI-Guided radiation may shield ovaries in young cancer patients
Knowledge-focused Recruiting nowThis study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
New imaging registry aims to sharpen cancer treatment precision
Knowledge-focused Recruiting nowThis study will collect data from 2,000 patients in the Netherlands and France who are receiving standard, minimally invasive cancer treatments like tumor ablation or catheter-based therapies for liver, lung, kidney, or bone cancers. During these procedures, a special CT scanner …
Sponsor: Mark C Burgmans, MD PhD • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Tiny coil placed inside nose could help surgeons spot hidden brain tumors
Knowledge-focused Recruiting nowThis study tests a small MRI coil placed inside the sphenoid sinus during pituitary tumor surgery. The goal is to see if it can provide clearer images of tiny tumors that standard MRI often misses. About 70 adults with pituitary tumors will take part. The coil is inserted through…
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Knowledge-focused
Last updated Sep 03, 2026 00:00 UTC
-
Study explores how medical info delivery shapes cancer care decisions
Knowledge-focused Recruiting nowThis study looks at how the way medical information is presented influences treatment choices for people with advanced cancer. About 400 participants will fill out questionnaires and review made-up case scenarios. The goal is to learn how to better communicate health options to e…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Yale launches massive blood repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects blood samples from people with cancer or at high risk for cancer to create a large, well-organized repository for research. The goal is to provide scientists with a valuable resource to study cancer through liquid biopsies, which may lead to better detection a…
Sponsor: Yale University • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Massive cancer DNA hunt aims to stop relapse before it starts
Knowledge-focused Recruiting nowThis study enrolls 7,000 people with various cancers who have had or will have treatment aimed at a cure. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA left behind. The goal is to find any remaining cancer as early as p…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
600 cancer patients to help unlock secrets of immunotherapy success
Knowledge-focused Recruiting nowThis study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Radiation's hidden toll: could it link tinnitus and hearing loss in cancer survivors?
Knowledge-focused Recruiting nowThis study looks at whether people treated with radiation (with or without chemotherapy) for head and neck cancer develop tinnitus (ringing in the ears) and hearing loss together. Researchers will follow about 140 patients for three months after treatment, measuring hearing and a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
A simple blood test may reveal hidden infertility risk in young cancer survivors
Knowledge-focused Recruiting nowThis study investigates whether a blood marker called anti-Müllerian hormone (AMH) can predict future infertility in children and adolescents who have undergone cancer treatment. Many young patients recover normal menstrual cycles or puberty after chemotherapy, but their ovarian …
Sponsor: Erasme University Hospital • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can immune markers predict success of docetaxel chemoradiotherapy?
Knowledge-focused Recruiting nowThis study looks at immune markers in tumor tissue, saliva, stool, and blood from 250 head and neck cancer patients who cannot receive cisplatin chemotherapy. Researchers want to see if these markers can predict how well patients respond to chemoradiotherapy with docetaxel. The g…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Pre-Surgery workout may boost recovery in head and neck cancer patients
Knowledge-focused Recruiting nowThis study looks at whether a supervised, home-based exercise program before surgery is possible and helpful for people with head and neck cancer. About 66 patients will take part, doing physical activities at home with weekly phone check-ins. The goal is to see if this approach …
Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Chewing comeback: prostheses tested in cancer survivors
Knowledge-focused Recruiting nowThis study follows 50 adults who have had head and neck cancer and now use custom dental prostheses. Researchers will measure how well they chew food and how their quality of life changes over time. The goal is to understand the real-world benefits of these prostheses for cancer …
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
Bacteria in the mouth and gut may predict who responds to cancer immunotherapy
Knowledge-focused Recruiting nowThis study looks at the bacteria living in the mouth, stool, and tumors of Colombian adults with advanced cancers of the stomach, colon, breast, cervix, or head and neck who are starting immunotherapy as standard care. Researchers will compare these microbial profiles to those of…
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Knowledge-focused
Last updated Jul 09, 2026 00:00 UTC
-
New approach aims to make repeat radiation safer for cancer patients
Knowledge-focused Recruiting nowThis study looks at a standardized method for giving high-dose radiation a second time to people with solid tumors that have come back. It uses advanced imaging to better calculate radiation doses to sensitive organs like the spinal cord and gut. The goal is to track how often se…
Sponsor: Medical College of Wisconsin • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Can a simple blood test predict leukemia risk after cancer therapy?
Knowledge-focused Recruiting nowThis study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC
-
Brain-Sparing radiation may shield young minds from treatment side effects
Knowledge-focused Recruiting nowThis study explores whether planning radiation therapy to avoid key brain regions can reduce thinking and learning problems in children with brain or head and neck tumors. Participants include children receiving radiation, survivors who completed radiation at least two years ago,…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Gene-Guided cancer therapy: a new hope for advanced tumors?
Knowledge-focused Recruiting nowThis study enrolls 1,000 adults with advanced solid tumors that have progressed after standard treatment. Researchers will use genetic tests to match patients to specific drugs, like Alectinib or Atezolizumab, based on their tumor's gene changes. The goal is to see if this person…
Sponsor: Seoul National University Bundang Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Rare sinus cancer study aims to clarify treatment outcomes
Knowledge-focused Recruiting nowThis study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …
Sponsor: Eye & ENT Hospital of Fudan University • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
770 cancer patients join study to unlock immunotherapy secrets
Knowledge-focused Recruiting nowThis study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…
Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Smart probe could help surgeons remove all cancer in one go
Knowledge-focused Recruiting nowThis study tests a device called SpiderMass that analyzes tissue molecules in real time during tongue cancer surgery. The goal is to help surgeons instantly tell cancerous from healthy tissue, so they can remove all the tumor in one operation. Currently, about 15-30% of patients …
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Scientists probe immune resistance in tumors to outsmart cancer
Knowledge-focused Recruiting nowThis study looks at 100 people with advanced solid tumors whose cancer stopped responding to immunotherapy. Researchers will take a fresh tumor sample and blood tests to compare genetic and immune differences between those who never responded and those who initially improved but …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
500 cancer patients join quest to unlock precision medicine secrets
Knowledge-focused Recruiting nowThis study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood biopsy study aims to improve cancer detection and monitoring
Knowledge-focused Recruiting nowThis study is looking at special markers in the blood (called biomarkers) to learn more about how to detect, diagnose, and track solid cancers. Researchers will collect blood samples from 6,000 adults with solid cancer and analyze them alongside standard tests. The goal is to see…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Proton therapy offers new hope for head and neck cancer patients facing second radiation
Knowledge-focused Recruiting nowSome head and neck cancer patients experience a tumor return in an area already treated with radiation. Surgery may not be an option, and standard radiation risks harming healthy tissue. This study tests proton therapy, which delivers radiation more precisely to the tumor while s…
Sponsor: Istituto Clinico Humanitas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Can a simple test predict immunotherapy success in head and neck cancer?
Knowledge-focused Recruiting nowThis study is collecting blood and tumor samples from 60 people with recurrent or metastatic head and neck cancer who are receiving standard anti-PD1 immunotherapy. The goal is to find biological markers that can predict whether the immunotherapy will work. Researchers will analy…
Sponsor: Centre Paul Strauss • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:03 UTC
-
Gut bacteria linked to cancer survivor symptoms?
Knowledge-focused Recruiting nowThis study follows 600 childhood cancer survivors aged 8-18 to understand why symptoms like fatigue, pain, and depression often occur together. Researchers will use questionnaires and stool samples to see if gut bacteria and their byproducts play a role. The goal is to find bette…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
10,000 cancer patients join ontario Gene-Mapping effort to personalize care
Knowledge-focused Recruiting nowThis study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:02 UTC
-
AI could make radiation therapy more precise by tracking tumors in real time
Knowledge-focused Recruiting nowThis study is developing an AI system that tracks tumors and organs during radiation therapy without needing physical markers. Researchers will use existing patient data to train and test the AI. If it works, it could help doctors target radiation more accurately. The study invol…
Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Scientists map immune cells in pituitary tumors to unlock new treatments
Knowledge-focused Recruiting nowThis study looks at the immune cells inside pituitary tumors to better understand how they behave. Researchers will analyze tumor samples from 60 adults who are having surgery to remove their pituitary tumor. The goal is to find clues that could lead to new immune-based treatment…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
300 patients tracked to uncover hidden cancer risks in common mouth condition
Knowledge-focused Recruiting nowThis study follows 300 people with oral lichen planus (a chronic mouth condition) for at least 6 months to see how often it turns into oral cancer. Researchers will also look for patterns and risk factors that might predict this change. No new treatments are tested—the goal is si…
Sponsor: Catholic University of the Sacred Heart • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
Personalized cancer care: DNA profiling guides patients to best trials
Knowledge-focused Recruiting nowThis study analyzes the DNA of solid tumors from 5,500 cancer patients to find genetic changes that could be targeted by specific treatments. The goal is to use this molecular profile to match patients with appropriate clinical trials. Participants must have a confirmed solid tum…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Can Off-Label drugs help when standard cancer therapy fails? new study aims to find out
Knowledge-focused Recruiting nowThis study is for people with advanced solid tumors who have run out of standard treatment options. Researchers will track how well off-label or non-standard therapies work when chosen based on the tumor's genetic profile. The goal is to create a standard way to measure responses…
Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Lab-Grown tumor clones could guide cancer therapy
Knowledge-focused Recruiting nowThis study aims to grow miniature versions of head and neck tumors, called organoids, from patient samples. Researchers will test different cancer drugs on these organoids to see which ones work best. The goal is to eventually use this approach to tailor treatments to each patien…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Blood particles may predict chemo nerve pain
Knowledge-focused Recruiting nowThis study is testing whether tiny particles in the blood, called extracellular vesicles, can predict nerve damage caused by chemotherapy. Researchers will follow 120 adults with various cancers who are receiving specific chemo drugs. Participants give blood samples and answer qu…
Sponsor: Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New study tracks Real-World care for sinonasal and Skull-Base tumours
Knowledge-focused Recruiting nowThis study is observing 120 patients with sinonasal or skull-base tumours at a specialist ear, nose, and throat centre. Researchers are tracking how these conditions are managed, what the outcomes are, and how patients' quality of life changes. The goal is to better understand cu…
Sponsor: University Medical Centre Ljubljana • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Can education help hispanic cancer survivors catch lung cancer early?
Knowledge-focused Recruiting nowThis study looks at how aware Hispanic/Latinx head and neck cancer survivors are about their risk of developing a second lung cancer and the recommended screening. Researchers will provide tailored education and conduct interviews to understand barriers to screening. The goal is …
Sponsor: University of Miami • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
New imaging study aims to sharpen radiotherapy for head and neck cancer
Knowledge-focused Recruiting nowThis study is testing whether advanced PET/MR imaging can help doctors personalize radiotherapy for head and neck cancer. Researchers will scan 390 patients before, during, and after treatment to see if imaging details can predict survival and response. The goal is to improve out…
Sponsor: Norwegian University of Science and Technology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
AI translates doctor speak for cancer patients
Knowledge-focused Recruiting nowThis study tests whether using artificial intelligence (AI) to rewrite medical discharge letters into plain language helps cancer patients better understand their diagnosis, treatment, and next steps. About 150 adults with blood cancer or other cancers will be randomly assigned t…
Sponsor: Technical University of Munich • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Cancer Patients' nutrition under the microscope: study tracks body changes during treatment
Knowledge-focused Recruiting nowThis study follows 110 adults with head and neck, lung, or rectal cancer to see how their nutrition and body composition change during standard cancer treatments. Researchers will measure food intake, muscle mass, and strength over time. The goal is to gather data that could late…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Blood test may reveal hidden tumor secrets in head and neck cancer
Knowledge-focused Recruiting nowThis study looks at whether a simple blood test can give the same information about a tumor's biology as testing the tumor tissue itself. Researchers will collect blood samples from 300 adults with HPV-negative head and neck cancer before and after standard treatment. They will c…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Massive european study launches to unlock secrets of rare head and neck cancers
Knowledge-focused Recruiting nowThis large observational registry aims to collect data from over 13,000 adults across Europe with rare head and neck cancers, including cancers of the nasopharynx, nasal cavity, salivary glands, and middle ear. Researchers will track patient outcomes like survival, treatment resp…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Scientists hunt for clues in blood and tumors to predict Cancer's next move
Knowledge-focused Recruiting nowThis observational study aims to understand why metastatic adenoid cystic carcinoma (ACC) of the head and neck behaves differently in different people. Researchers will analyze stored tumor tissue and blood samples from 114 adults to see if certain biological types (ACC-I or ACC-…
Sponsor: Fondazione IRCCS Istituto Nazionale dei Tumori, Milano • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Massive study aims to predict brain surgery success
Knowledge-focused Recruiting nowThis study is gathering information from 4500 people who have or will have brain surgery for conditions like aneurysms, tumors, epilepsy, and Parkinson's disease. The goal is to find patterns that help doctors predict how well someone will recover. By standardizing how outcomes a…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Could a simple Height-Based adjustment make tumor ablation safer?
Knowledge-focused Recruiting nowThis study looks at how to set the breathing machine (jet ventilator) during a procedure that destroys tumors with heat or cold. The goal is to find the best air pressure setting to keep patients breathing well while the doctor works precisely. About 560 adults having tumor ablat…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New tool aims to predict cancer treatment toxicity in older patients
Knowledge-focused Recruiting nowThis study is testing a new tool designed to predict side effects from cancer treatment in elderly patients (70+) with advanced head and neck cancer. The goal is to see if the tool can help doctors choose safer treatments. Only 3 participants are being enrolled, making this a ver…
Sponsor: European Institute of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
New registry to monitor ion beam therapy results
Knowledge-focused Recruiting nowThis registry study is collecting data from 2,800 cancer patients treated with ion beam therapy (protons and carbon ions) at MedAustron. Researchers will track tumor response, survival, side effects, and quality of life over time. The goal is to better understand the real-world b…
Sponsor: EBG MedAustron GmbH • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Lab-Grown tumor avatars could pick the right cancer drug for each patient
Knowledge-focused Recruiting nowThis study tests a personalized approach for patients with advanced liver or colorectal cancers that no longer respond to standard treatments. Doctors take a small sample of the tumor, grow it in the lab as 3D 'organoids', and test different drugs on them to see which works best.…
Sponsor: Chinese University of Hong Kong • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Scientists hunt for immune clues in rare salivary gland cancers
Knowledge-focused Recruiting nowThis study is for 300 people with salivary gland tumors (both cancerous and non-cancerous) to learn how the immune system reacts to these rare cancers. Researchers will collect tumor tissue and blood samples before and after treatment to find immune markers that might predict how…
Sponsor: University of Erlangen-Nürnberg Medical School • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Can MRI make cancer radiation smarter? new study investigates
Knowledge-focused Recruiting nowThis study is testing whether repeated MRI scans during radiation therapy for head and neck cancer can help doctors see how the tumor is responding. About 173 people with newly diagnosed head and neck cancer will get extra MRI scans during their standard treatment. The goal is to…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
8,000-Patient study aims to sharpen cancer radiation with Real-Time MRI
Knowledge-focused Recruiting nowThis study is a large registry that will follow about 8,000 cancer patients who receive radiation therapy using a special machine called an MR-Linac, which combines an MRI scanner with a radiation beam. The goal is to learn how well this technology works for different cancers, in…
Sponsor: UMC Utrecht • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can a PET scan predict if immunotherapy works? new study aims to find out
Knowledge-focused Recruiting nowThis study is testing whether a special PET scan taken 6 weeks after starting pembrolizumab (an immunotherapy drug) can predict how well the drug works at 3, 6, and 9 months in people with advanced head and neck cancer. Researchers will enroll 25 patients whose cancer has returne…
Sponsor: University of Rome Tor Vergata • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
New study explores why cancer patients lose their appetite
Knowledge-focused Recruiting nowThis study looks at how cancer and its treatments change a person's sense of taste and smell, and how that affects their eating and nutrition. Researchers will follow 306 people newly diagnosed with cancer of the mouth, throat, colon, or liver. They will use questionnaires, taste…
Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC